CLOSE ×

Cell line references

Tissue sub-type Cell line References Mice Models Rat Models
Cancer Stem Cells (Human Tissue)
Adenocarcinoma A549 535 B-NDG
Adenocarcinoma H1975 535 B-NDG
Brain BTSC83 200 nude
Brain Glioblastoma 331, 341, 343, 432 NOD.SCID, nude
Brain LA-N-5 231 nude
Brain NGC-407-GFP 206 nude
Brain U87-SC 232 nude
Breast 2LMP (MDA-MB-231 subclone) 234 NOD.SCID
Breast BCM-2147 340, 577 SCID-beige
Breast BCM-2665 340 SCID-beige
Breast BCM-3887 340 SCID-beige
Breast BCM-4195 340 SCID-beige
Breast MCF-7 (CSC-like) 236 nude
Breast MCF-7 (mammospheres) 235 nude
Breast SUM159 234, 629 NOD.SCID, nude
Breast NMuMG-RFP 486 NOD.SCID
Breast E1KD-GFP 486 NOD.SCID
Breast (mammary) LTR-MycER DCIS 482 NOD-SCID
Colon Colon tumor tissue 428 NOD.SCID
Gastric GSC1 471 SCID-beige
Glioma CD133 462 SCID-beige
Glioma OCT4/SOX2 462 SCID-beige
Lung A549 108, 501, 573 nude
Lung H1299 108, 573 nude
Ovarian A2780-CR5 [ALDH(+) and ALDH(-)] 350 nude
Ovarian SKOV-3 (spherical cells) 213 BALB/c nude
Prostate DU-145 (spheroid cells) 233 NOD.SCID
Human Tissue
Bladder KU-7 148, 149, 150, 151 nude
Bladder T24 52, 478, 591 NOD.SCID, nude nude
Bladder T24- Luc 531 B-NDG
Bladder UM-UC1 278 nude
Bladder UM-UC13 278 nude
Bladder UM-UC3 278 nude
Bladder RT4 478 NOD.SCID
Bladder HT-1376 478 NOD.SCID
Bladder 5637 478 NOD.SCID
Bladder 5637-Luc 551 B-NDG
Bladder H157 464 SCID-beige
Bladder H1299 464 SCID-beige
Brain A-172 198 nude
Brain G55 3, 445 nude nude
Brain GL15 286 C.B-17 SCID
Brain HTLA-230 5, 125 SCID-beige, nude
Brain SH-SY5Y 2, 563 nude nude
Brain TB10 200 nude
Brain U251 81, 202, 414, 422, 427 nude nude
Brain U251 MG 198, 199, 550 nude, B-NDG
Brain U251-NG2 1, 285 nude
Brain U87 71, 81, 117, 173, 196, 414, 450, 529, 566, 615, 680 NMRI nude, nude, SCID, SCID-beige nude, RAG2 KO(SD)
Brain U87ΔEGFR 197 nude
Brain U87MG 4, 78, 80, 83, 133, 134, 164, 195, 198, 201, 205, 206, 209, 224, 249, 342, 404, 427, 550, 596 BALB/c SCID, beige-nude-xid, CD-1 nude, NMRI nude, nude, SCID, B-NDG nude
Brain U87Fluc 79, 82 BALB/c nude, nude
Brain U87MG.wt EGFR 203 nude
Brain U87-TARTK 208 NOD.SCID
Brain U138MG 203, 266 NOD.SCID, nude
Brain U373 207 nude
Brain SH-EP 443 nude
Brain WAC2 443 nude
Brain D341 Med 524 nude
Brain D384 Med 524 nude
Brain D425 Med 524 nude
Brain (astrocytoma) U87 528 RAG2 KO(SD)
Brain (diffuse intrinsic pontine glioma) TT150630 546 B-NDG
Brain (diffuse intrinsic pontine glioma) TT150728 546 B-NDG
Breast 231/LM2-4 353 nude
Breast BT-474 61, 62, 72, 143, 157, 160, 161, 162,163, 165, 211, 227, 228, 258, 270, 601 BALB/c nude, nude, C.B-17 SCID, SCID-beige
Breast BT-474C 299 nude nude
Breast BT474-EEI 252, 556 beige-nude-xid
Breast BT-474-M1 178, 253, 254, 257, 288 beige-nude-xid, nude, SCID
Breast BT-474/TR 161, 162 nude
Breast HCC1569 162 nude
Breast JIMT-1 68, 69, 226, 289 C.B-17 SCID, NMRI nude, nude, SCID
Breast KPL-4 143, 627, 667 nude, SCID-beige, NOD.SCID
Breast MCF-7 8, 14, 24, 97, 103, 128, 130, 131, 132, 138, 143, 146, 192, 210, 217, 218, 219, 226, 229, 230, 255, 256, 290, 308, 309, 310, 311, 312, 313, 354, 412, 468, 608, 629 BALB/c nude, CD-1 nude, MF1 nude, nude, SCID, SCID-beige, SHrN® nude
Breast MCF-GFP 349 nude
Breast MCF-RSK4 349 nude
Breast MCF/HER2-18 160 nude
Breast MDA-MB-175 253 beige-nude-xid
Breast MDA-MB-231 9, 11, 12, 15, 56, 71, 94, 111, 116, 136, 139, 143, 156, 174, 176, 177, 184, 185, 186, 187, 188, 189, 190, 191, 193, 209, 217, 267, 287, 299, 354, 408, 431, 442, 454, 481, 504, 510, 516, 624, 625, 678 BALB/c SCID, CD-1 nude, nude, NOD.SCID, SCID, SCID-beige, CB-17 nude
Breast MDA-MB-231-mCherry 282 nude
Breast MDA-MB-231-Luc 477, 575, 611 NOD.SCID
Breast MDA-MB-361 60, 256, 313 nude
Breast MDA-MB-435 12 nude
Breast MDA-MB-453 158, 256 nude
Breast MDA-MB-468 226, 260, 266, 421, 581, 667 nude, NOD.SCID, SCID
Breast MEF-p95-HER2 64 nude
Breast MT-1 13, 170, 245 CD-1 nude, nude nude
Breast T47D 6, 7, 130, 210, 229, 259, 310, 313, 402 BALB/c nude, nude, SCID-beige
Breast ZR-75-1 299, 429 nude, NOD.SCID nude
Breast BT549 442 nude
Breast MIV-shSCR 480 NOD.SCID
Breast MIV-INHBA 480 NOD.SCID
Breast CACNA1H 500 NOD.SCID
Breast MCF-7eGFP 515 nude
Breast MCF-7FGFR1 515 nude
Breast MCFDCIS 518 nude
Breast BT-474R2 527 nude
Cervical HeLa 78, 124, 344, 346, 347, 449 nude nude
Cervical Hep-2 (HeLa contaminant) 345 BALB/c nude
Cervical ME-180 291 nude
Cervical SiHa 291, 588 nude
Carcinoma HCC95 517 nude
Carcinoma KYSE-180 517 nude
Carcinoma CMV-luciferase 552 B-NDG
Carcinoma Sk-HEP-1 (nano-Luc+) 553 B-NDG
Colon BCS-TC2.2 113 nude
Colon Colo201 338 nude
Colon Colo205 180, 299 nude, NOD.SCID nude
Colon Colo320 113 nude
Colon Colo320-CD9 113 nude
Colon GEO 143, 258, 338 nude, SCID-beige
Colon HCA-7 17 nude
Colon HCT-15 338 nude
Colon LoVo 116, 299 nude nude
Colon LS174T 63, 140, 159, 392 nude
Colon MV522 180 nude, NOD.SCID
Colon SW480 122 SCID
Colon SW48 509, 604 nude
Colon LIM1215 509 nude
Colorectal CX-1 20 nude
Colorectal DLD-1 16, 152, 243, 294, 651 nude, B-NDG
Colorectal HCT-116 17, 18, 19, 112, 143, 153, 164, 413, 419, 564, 604 nude, SCID, SCID-beige, B-DNG
Colorectal HT-29 16, 22, 23, 114, 115, 116, 117, 141, 143, 147, 239, 263, 295, 299, 347, 564, 571 BALB/c nude, beige-nude-xid, NMRI nude, nude, SCID-beige nude
Colorectal SW620 243, 294, 578 nude
Endometrial ECC-1 312 nude
Esophageal FLO-1 172, 559 nude
Esophageal OE19 126, 127, 138, 154, 175 BALB/c nude, MF1 nude, nude, SCID
Esophageal OE21 154 nude
Esophageal OE33 154, 155, 172 nude
Esophageal OE47 154 nude
Fibrosarcoma HT1080 77, 124, 209, 406, 607 BALB/c SCID, nude
Gastric MKN45 124 nude
Gastric N87 70, 143, 164, 175, 258, 461, 619 NMRI nude, nude, SCID, SCID-beige
Gastric HS746T 417 nude
Gastric OE-19 461 SCID-beige
Gastric JIMT-1 461 SCID-beige
Gastric RN-87 461 SCID-beige
Gastric ROE-19 461 SCID-beige
Gastric SNU-216 461 SCID-beige
Gastrointestinal GIST-T1 436 SCID-beige
Glioma H157 464 SCID-beige
Glioma H1299 464 SCID-beige
Head & Neck Squamous Cell Carcinoma (HNSCC) Cal-27 65, 66, 67 nude
Head & Neck Squamous Cell Carcinoma (HNSCC) CCL 23 (HeLa contaminant) 67 nude
Head & Neck Squamous Cell Carcinoma (HNSCC) FaDu 21, 65, 244, 555, 582 nude nude
Head & Neck Squamous Cell Carcinoma (HNSCC) HeLa-O3 330 nude
Head & Neck Squamous Cell Carcinoma (HNSCC) HNX-OE 21 nude
Head & Neck Squamous Cell Carcinoma (HNSCC) SCC-1 284 nude
Head & Neck Squamous Cell Carcinoma (HNSCC) UM-SCC1 66, 67, 116, 284 nude
Head & Neck Squamous Cell Carcinoma (HNSCC) UMSCC38 279 nude
Head & Neck Squamous Cell Carcinoma (HNSCC) WSUHN-31 60 nude
Head & Neck Squamous Cell Carcinoma (HNSCC) SE-Pt#1 479 NOD.SCID
Head & Neck Squamous Cell Carcinoma (HNSCC) SE-Pt#2 479 NOD.SCID
Head & Neck Squamous Cell Carcinoma (HNSCC) SE-Pt#3 479 NOD.SCID
Head & Neck Squamous Cell Carcinoma (HNSCC) SE-Pt#4 479 NOD.SCID
Head & Neck Squamous Cell Carcinoma (HNSCC) SE-Pt#5 479 NOD.SCID
Head & Neck Squamous Cell Carcinoma (HNSCC) SE-Pt#6 479 NOD.SCID
Leukemia ARH-77 298 C.B-17 SCID
Leukemia HEL9217 57 C.B-17 SCID
Leukemia HL60 57, 171 C.B-17 SCID
Leukemia HPB-ALL 27 nude
Leukemia K562 171, 396, 545 C.B-17 SCID, SHrN®, B-NDG
Leukemia KG-1 144 C.B-17 SCID
Leukemia MV4-11 166, 179, 180, 181, 182, 296, 348 NOD.SCID, nude nude
Leukemia TF1-α 57 C.B-17 SCID
Leukemia THP-1 75 C.B-17 SCID
Leukemia ERY-1 502 nude
Leukemia GFP‐labeled Reh PRPS1 547 B-NDG
Leukemia NALM6 ALL 549 B-NDG
Leukemia Reh ALL 549 B-NDG
Leukemia (acute myeloid) RUVBL1/2 465 SCID-beige
Leukemia (acute myeloid) AML 466 SCID-beige
Leukemia (acute myeloid) AML1-ETO 512 nude
Liver AKH10 307 SCID-beige
Liver Hep3B 25, 101, 119, 137, 222, 223, 225, 392 nude nude
Liver Hep-G2 122, 548 SCID, B-NDG
Liver HepT1 25 nude
Liver HuCCT1 262 nude
Liver HuH6 26, 411, 415, 506 nude nude
Liver Huh-7 122 SCID
Liver KFJ6 307 SCID-beige
Liver KFJ9 307 SCID-beige
Liver KFJ10 307 SCID-beige
Liver COA67 506 nude
Lung adenocarcinoma H157 464 SCID-beige
Lung adenocarcinoma H1299 464 SCID-beige
Lung A549 9, 11, 15, 33, 109, 110, 117, 122, 143, 183, 244, 258, 416, 472, 492, 514, 691 NMRI nude, nude, SCID, SCID-beige, NOD.SCID nude
Lung A549m 279 nude
Lung BEN 88 SCID-beige
Lung Calu6 142, 143, 299, 604 NOD.SCID, SCID-beige, nude nude
Lung Colo-699 34, 88, 89 SCID-beige
Lung H226B 279 nude
Lung H358 31, 595 nude
Lung KNS-62 34, 88, 89 SCID-beige
Lung L2987 143 SCID-beige, nude
Lung LX-1 143 SCID-beige, nude
Lung NCI-H460 114, 225, 293, 297 C.B-17 SCID, nude nude
Lung NCI-H69 143, 354, 615 nude, SCID-beige, SHrN®
Lung NCI-H82 118, 615 nude
Lung NCI-H841 354 SHrN®
Lung NCI-N417 32 nude
Lung PC-9/BRc1 351 nude
Lung H292 407 nude
Lung H865 409 nude
Lung H2122 507 nude
Lung TC1 Luc 519 nude
Lymphoma (non-Hodgkin's) DoHH2 435 C.B-17 SCID
Lymphoma (non-Hodgkin's) Ramos 435, 664, 665 C.B-17 SCID
Lymphoma (non-Hodgkin's) WSU-DLCL2 435 C.B-17 SCID
Lymphoma (non-Hodgkin's) Raji 120, 121, 182, 643 NOD.SCID, SCID
Lymphoma (non-Hodgkin's) L-428 511 nude
Lymphoma CA46 144 SCID
Lymphoma Granta 519, 30, 144 SCID
Lymphoma Karpas-299 28, 90, 542, 654 SCID, B-NDG
Lymphoma Raji 542, 543, 643, 646 B-NDG
Lymphoma L540cy 28 SCID
Lymphoma SP53 30 SCID
Lymphoma Z138 238 SCID
Lymphoma Human Lymphoma B (P493) 453 CB-17
Lymphoma Nalm6 472 SCID-beige
Lymphoma REC-1 520 nude
Lymphoma SU-DHL-2 538 B-NDG
Melanoma 518A2 122, 247, 319, 321 C.B-17 SCID, SCID
Melanoma 537MEL 323 beige-nude-xid
Melanoma 607B 247 SCID
Melanoma A2058 318 SCID
Melanoma A375 163, 281, 306, 316 nude
Melanoma A375M 249 nude
Melanoma DM6 85 nude
Melanoma FM82 320 NOD.SCID
Melanoma Ge 248 SCID-beige
Melanoma Mel-JUSO 247 SCID
Melanoma MelM9 322 C.B-17 SCID
Melanoma NIH1286 84 nude
Melanoma SIT1 37 SCID
Melanoma SK-MEL23 323 beige-nude-xid
Melanoma SK-MEL23/155 495 NOD.SCID
Melanoma UACC 903, 315 nude
Melanoma VM 317 BALB/c SCID
Melanoma hCMEC/D3 476 NOD-SCID
Melanoma SC-1800 476 NOD-SCID
Melanoma H1 (or H1_DL2) 476 NOD-SCID
Melanoma H2 476 NOD-SCID
Mesothelioma DEVy 100 nude
Mesothelioma shNT-Gpx4 iKO-TGL MSTO-211H 487 NOD.SCID
Mesothelioma hMerlin-Gpx4 iKO-TGL MSTO-211H 487 NOD-SCID
Mesothelioma shNT HCT116 525 nude
Mesothelioma shLats1/2 HCT116 525 nude
Multiple Myeloma ARP-1 144 SCID
Multiple Myeloma KAS-6/1 76 SCID
Multiple Myeloma L-363 120 SCID
Multiple Myeloma LAGΛ-1 74, 75 nude
Multiple Myeloma MM.1S 120, 144, 399, 489, 493 C.B-17 SCID, SCID
Multiple Myeloma MPC-11 325 beige-nude-xid
Multiple Myeloma NCI-H929 242 NOD.SCID
Multiple Myeloma RPMI 226, 303, 304, 305 C.B-17 SCID, SCID
Multiple Myeloma U266 242, 489 NOD.SCID
Multiple Myeloma RUVBL1/2 465, 508 SCID-beige, nude
Multiple Myeloma NCI-H929 489, 493 NOD.SCID
Multiple Myeloma RPMI-8226 489, 669, 670 NOD.SCID
Multiple Myeloma OPM-2 489 NOD.SCID
Multiple Myeloma AMO-1 489 NOD.SCID
Multiple Myeloma JJN3 497 NOD.SCID
Multiple Myeloma NEK2‐OE KMS11 537, 670 B‐NDG, NOD.SCID
Neuroblastoma COA3 484, 565 NOD.SCID, nude
Neuroblastoma COA6 484, 565 NOD.SCID, nude
Oral 686LN 279 nude
Oral KB (HeLa contaminant) 299 nude nude
Osteosarcoma OS-17 433 C.B-17 SCID
Osteosarcoma 143B 405, 433 C.B-17 SCID
Ovarian A2780 434 C.B-17 SCID
Ovarian 1A9 78 nude
Ovarian 1A9ptx10 78 nude
Ovarian A2780 143, 350 nude, SCID-beige
Ovarian CAOV3 87 nude
Ovarian CD228 143 nude, SCID-beige
Ovarian HEY 269 nude
Ovarian MW387 143 nude, SCID-beige
Ovarian NMP-1 96 nude
Ovarian OVA-1 91 SCID
Ovarian OVCAR-3 39, 73, 98, 99, 45, 456, 631, 668 NMRI nude, nude, SCID-beige
Ovarian OVCAR4 522 nude
Ovarian OVCAR8 458 SCID-beige
Ovarian PA354 143 nude, SCID-beige
Ovarian SKOV-3 38, 40, 41, 55, 86, 92, 93, 95, 211, 212, 213, 214, 292, 324 BALB/c nude, beige-nude-xid, nude, SCID, NOD.SCID nude
Ovarian SKOV3-luc 237, 446, 632, 642 nude, B-NDG nude
Ovarian fLuc+ SK-OV-3 539 B-NDG
Pancreatic AsPC-1 299 nude nude
Pancreatic BxPC-3 42, 275, 276, 572 nude
Pancreatic BxPC3/vector 276, 280 nude
Pancreatic BxPC3/shSTAT3 280 nude
Pancreatic Bx/shRON 276 nude
Pancreatic CFPAC-1 43, 394 nude
Pancreatic Colo357 42, 44, 251 nude, SCID-beige
Pancreatic HPAC 299 nude nude
Pancreatic L3.6pl 123, 236 nude
Pancreatic MIA-Luc 202 nude
Pancreatic MIA PaCa-2 54, 167, 277, 420, 558,572, 595, 604, 652 nude, B-NDG
Pancreatic PANC-1 42, 167, 168, 491 ,597 nude, NOD.SCID
Pancreatic Panc185 272 nude
Pancreatic Panc89 45 SCID
Pancreatic Panc430 262 nude
Pancreatic PL45 43 nude
Pancreatic T3M4 42 nude
Prostate CWR22 51, 143, 623 nude, SCID-beige
Prostate DU-145 29, 211, 221, 679 ICR-SCID, nude, SCID-beige
Prostate LAPC4 107, 352 nude
Prostate LNCaP 50, 104, 105, 106, 194, 223, 246, 326, 410, 430, 494, 594, 609, 671 nude, C.B-17 SCID, SCID, NOD.SCID
Prostate LuCap35 143 nude, SCID-beige
Prostate MDA-PCa-2b 143 nude, SCID-beige
Prostate PC-3 46, 47, 48, 49, 129, 135, 138, 143, 169, 209, 211, 216, 220, 240, 246, 283, 302, 513, 562, 594, 596 BALB/c nude, BALB/c SCID, beige-nude-xid, MF1 nude, nude, SCID, SCID-beige
Prostate PC-3M 164 nude
Prostate VCaP 215, 513 nude
Prostate 22Rv1 513, 583 nude
Prostate C4-2 513, 583 nude
Prostate ARCaPM 521 nude
Prostate LNCaP-HSD17B2 541 B-NDG
Renal 786O 127, 138, 180, 654 BALB/c nude, MF1 nude, NOD.SCID, nude
Renal ACHN 328 NOD.SCID
Renal Caki-1 444, 605 nude
Renal Caki-1 CLDN7-Luc 533 B-NDG
Renal Caki-2 329 nude
Renal SK-NEP-1 415 nude
Renal MRKT 415 nude
Renal G401 415 nude
Renal Primary (Immortalized) 439 SCID-beige
Renal SMMC-7721-luciferase 534 B-NDG
Retinoblastoma Y79 241 nude
Sarcoma SK-LMS-1 523 nude
Skin (HPV16)BC-1-Ep/SL-LF 314 beige-nude-xid, nude, SHrN®
Skin (benign) Shope papilloma 301 nude
Skin (Merkel Cell Carcinoma) MCPyV-positive MCC cell lines 483 NOD.SCID
Squamous-cell/epidermoid carcinoma A431 143, 211, 262, 264, 265, 266, 267, 268, 412 NOD.SCID, nude, SCID-beige
Testicular NCCIT 53 nude
Thyroid CAL62 496 NOD.SCID
Thyroid CAL62-splice cells 496 NOD.SCID
Thyroid H1299 464 SCID-beige
Thyroid H157 464 SCID-beige
Uveal melanoma M619 102 SCID
Uveal melanoma MUM2B 102 SCID
Uveal melanoma OCM1a 102 SCID
Vulva A431 327, 345 BALB/c nude, NOD.SCID
Vulva SK-LMS-1 145 nude
Colon LS411N 392 nude
Colon SW403 392 nude
Pancreatic CFPAC-1 394 nude
Lung H226 (NSCLC) 395 nude
Head & Neck Squamous Cell Carcinoma (HNSCC) SCC1483 395 nude
Head & Neck Squamous Cell Carcinoma (HNSCC) SCC1 (cetuximab-resistant) 395 nude
Brain GS-11 397 SHrN®
Lymphoma MUTU-1 398 C.B-17 SCID
Brain T87 GSC 400, 425 nude
Breast MDA-IBC3 401 SCID-beige
Breast SUM149 401 SCID-beige
Head & Neck Squamous Cell Carcinoma (HNSCC) Cal33 555 nude
Prostate PC3M-Luc 560 nude
Breast GPX4 iKO BT474 562 nude
Head and neck, breast PDX 567 nude
Brain IMR32 568 nude
Lung Cancer HCC827 HCC827-ER1 570 nude
Pancreatic PANC-1-luc 572 nude
Ovarian PDX 574, 672, 684 nude
Lymphoma SUP-T1-luc 576 nude
Breast shOBR-MCF-7 579 nude
Breast shOBR MDA-MB-231 579 nude
Ovarian ES2 580 nude
Breast AU565 581 nude
Adrenal H295R 584 nude
Lung A549-Red-FLuc Bioware® Brite Cell Line 585 nude
Lung A549shHTATIP2 586 nude
Lung A549-luc 587, 645 nude, NOD.CB17-Prkdcscid IL2rgtm1/BcgenHsd
Glioblastoma G9pCDH-copGFP 590 nude
Bladder J82-Ras 591 nude
Prostate PC3 560 nude
Prostate PAC120 594 nude
Prostate CDX 594 nude
Glioblastoma NCH421K 596 nude
Glioblastoma P13 596 nude
Glioblastoma P3-stem cell-like 596 nude
Glioblastoma P22 596 nude
Glioblastoma DBTRG-shCtr, DBTRG-shΔNp73 598 nude
Glioblastoma SJGBM2-Ctr, SJGBM2-ΔNp73 598 nude
Glioblastoma SJGBM2-luc 598 nude
Glioblastoma CHLA-200 598 nude
Neuroblastoma SK-N-BE(2)  600 nude
Ovarian OV90-KRCCshRNA, OC90-ctrl 603 nude
Melanoma SK-MEL30 604 nude
Colon KM-12 606 nude
Breast MDA-MB-231-shFBXO44 611 nude
Ovarian OV8-mcherry 612 nude
Pancreatic Panc354 614 nude
Brain U87-CXCR4 615 nude
Lymphoma (PCNSL-primary CNS lymphona) PCNSL-5 615 nude
Lymphoma (PCNSL-primary CNS lymphona) PCNSL-6 615 nude
Lymphoma (PCNSL-primary CNS lymphona) PCNSL-10 615 nude
Lymphoma (PCNSL-primary CNS lymphona) PCNSL-11 615 nude
Lymphoma (PCNSL-primary CNS lymphona) PCNSL-12 615 nude
Lymphoma (PCNSL-primary CNS lymphona) PCNSL-14 615 nude
Lymphoma (PCNSL-primary CNS lymphona) PCNSL-15 615 nude
Lymphoma (PCNSL-primary CNS lymphona) PCNSL-16 615 nude
Lymphoma (PCNSL-primary CNS lymphona) PCNSL-14 615 nude
Lymphoma (PCNSL-primary CNS lymphona) PCNSL-14 615 nude
Breast MDA-MB-231-shYBX1 616 nude
Breast MDA-MB-231-GFP 617 nude
Kidney HEK-SST2 618, 621 nude
Kidney HEK-SST5 618, 621 nude
Oral squamous cell carcinoma HSC-3 GFP/Luc 620 nude
Glioma BT3 622 nude
Prostate CWR22-MEIS1 623 nude
Prostate CWR22-HOXB13ko 623 nude
Prostate CWR22-HOXB13ko 623 nude
Breast SK-BR3 630, 665 nude, C.B-17 SCID
Glioma HSJD-DIPG-007 633 nude
Lung NCI-H441 643 B-NDG
Hematopoetic iTregs 647 B-NDG
Multiple Myeloma U266-GFP-Luc 649 B-NDG
Colorectal DLD-1-HDAC2 KO 651 B-NDG
Colorectal DLD-1-HDAC2 KO-shH19 651 B-NDG
Colorectal DLD-1-HDAC2 KO-shH19 651 B-NDG
Pancreatic S2VP10 655 C.B-17 SCID
Pancreatic S2CP9 655 C.B-17 SCID
Multiple Myeloma MM.1S-Luc 656 C.B-17 SCID
Ovarian KRCH31 660 C.B-17 SCID
Ovarian SARARK9 661 C.B-17 SCID
Uterine serous carcinoma ARK2 663 C.B-17 SCID
Uterine serous carcinoma CCL-155 664 C.B-17 SCID
Teratoma Multipotent mesenchymal stromal cells (MSC) 674 NOD.SCID
Thyroid THJ‐16T 676 R2G2®
Leukemia MEC-2 677 R2G2®
Multiple Myeloma MM.1S-GFP 686 SCID-beige
Leukemia HMC1.1 688 SCID-beige
Leukemia HMC1.2 688 SCID-beige
Leukemia RPMI 8666 688 SCID-beige
Patient-Derived Tumors (Human Tissue)
Breast WHIM18 (luminal) 689 SCID-beige
Breast WHIM20 (luminal) 689 SCID-beige
Brain (PDX) 271, 426, 626, 662 nude, C.B-17 SCID nude
Brain U87MG (GBM PDX) 337 nude
Breast BMC-2147 274 SCID-beige
Breast HBCX 1 270 nude
Breast HBCX 6 270 nude
Breast HBCX 7 270 nude
Breast HBCX 9 270 nude
Breast HBCX 12B 270 nude
Breast HBCX 17 270 nude
Breast HBCx-3 339 BALB/c nude
Breast HBCx-4A 339 BALB/c nude
Breast HBCx-8 339 BALB/c nude
Breast HBCx-24 339 BALB/c nude
Breast HBCx-30 339 BALB/c nude
Breast PDX60 349 NMRI nude
Breast PDX156 349 NMRI nude
Breast MC1 274, 683 SCID-beige
Breast TNBC (MC1) 273 NOD.SCID
Breast BCM-2147 440, 577, 683 SCID-beige, nude
Breast BCM-4013 440, 577, 683 SCID-beige, nude
Breast BCM-4888 469, 683 SCID-beige
Breast BCM-4272 469, 683 SCID-beige
Breast BCM-3887 469, 683 SCID-beige
Breast SUM149 441 SCID-beige
Breast HCI-001 442 NOD.SCID
Breast HCI-010 442 NOD.SCID
Breast HMEC 455 SCID-beige
Breast A73 473 SCID-beige
Breast E0771 473 SCID-beige
Breast E0771-ICBR 473 SCID-beige
Breast PyMT-M 473 SCID-beige
Breast PyMT-N 473 SCID-beige
Breast PyMT-M-ICBR 473 SCID-beige
Breast PDX-1079 474 CB-17
Breast PDX-9327 474 CB-17
Breast PDX-1173 474 CB-17
Breast SUM149PT 499 NOD.SCID
Breast HCC1428 499 NOD.SCID
Breast MDAMB468 499 NOD.SCID
Breast ZR751 499 NOD.SCID
Breast PDX PT1-17 503 nude
Breast MCF7 526 nude
Breast HIM3 526 nude
Carcinoma (Intrahepatic cholangiocarcinoma) PDX0044 (ICC PDX) 540 B-NDG
Colorectal (BRAF mutant PDX) 332 NMRI nude
Colorectal (KRAS mutant PDX) 332 NMRI nude
Colorectal (PIK3CA mutant PDX) 332 NMRI nude
Colorectal (PTEN mutant PDX) 332 NMRI nude
Colorectal CUCRC006 338 nude
Colorectal CUCRC026 338 nude
Colorectal CUCRC036 338 nude
Colorectal CUCRC042 338 nude
Colorectal CUCRC047 338 nude
Colorectal CUCRC040 (KRAS mutant PDX) 336 nude
Colorectal CUCRC042 (KRAS/PIK3CA mutant PDX) 336 nude
Colorectal CUCRC108 (KRAS mutant PDX) 336 nude
Colorectal CUCRC125 336 nude
Colorectal PDX 530 B-NDG
Glioblastoma GMB-05 475 NOD.SCID
Glioblastoma GMB-06 475 NOD.SCID
Glioblastoma GMB-07 475 NOD.SCID
Glioma GMB-derived 485 NOD.SCID
Head & Neck Squamous Cell Carcinoma (HNSCC) PDX-SE1 490 NOD.SCID
Head & Neck Squamous Cell Carcinoma (HNSCC) PDX-SE3 490 NOD.SCID
Liver AKH23 307 SCID-beige
Liver KFJ18 307 SCID-beige
Lung (NSCLC PDX) 272, 624 NOD.SCID, nude
Lung (SCLC PDX) 536, 544 B-NDG
Lung p2 SCLC PDXact 354 NOD.SCID
Melanoma H1 488 NOD.SCID
Melanoma H2 488 NOD.SCID
Melanoma H3 488 NOD.SCID
Melanoma H10 488 NOD.SCID
Neuroblastoma SK-N-SH 451 CB-17
Ovarian (ovarian, primary peritoneal, or fallopian tube cancer PDX) 437, 438, 681 SCID-beige, nude
Ovarian PAPP-A 457 SCID-beige
Ovarian OVCAR-8 460 SCID-beige
Ovarian PH026 467, 690 SCID-beige
Ovarian PH048 467 SCID-beige
Ovarian PH212 467 SCID-beige
Pancreatic JH033 272 nude
Pancreatic Panc194 335 nude
Prostate KRAS PANC-1 459 SCID-beige
Prostate 1B 333 nude
Prostate 2B 333 nude
Prostate 2T 333 nude
Prostate 3B 333 nude
Prostate 3T 333 nude
Prostate 4B 333 nude
Prostate 4T 333 nude
Prostate LuCaP35CR 410 nude
Prostate C4-2B 452 CB-17
Prostate DU145 452 CB-17
Prostate C4-2B-TaxR 452 CB-17
Prostate DU145-TaxR 452 CB-17
Sarcoma (Chondrosarcoma PDX) 334 nude, C.B-17 SCID
Sarcoma (Ewing sarcoma PDX) 334, 662 nude
Sarcoma (Leiomyosarcoma PDX) 334 nude
Sarcoma (Liposarcoma PDX) 334 nude
Sarcoma (Multifocal sarcoma PDX) 334 nude
Sarcoma (Myxoma PDX) 334 nude
Sarcoma (Phyllodes sarcoma PDX) 334 nude
Sarcoma (Rhabdomyosarcoma PDX) 334, 662 nude, C.B-17 SCID
Sarcoma (Small round cell sarcoma PDX) 334 nude
Sarcoma (Spindle cell sarcoma PDX) 334 nude
Sarcoma (Synovial sarcoma PDX) 334 nude
Kidney (Renal Cell Carcinoma PDX) 393 nude
Oral (Floor of Mouth Squamous Cell Carcinoma PDX) 395 nude
Thyroid BCPAP 448 nude
Thyroid TPC-1 448, 463, 628 SCID-beige, nude nude
Thyroid CUTC5 470, 505 SCID-beige, nude
Thyroid CUTC48 470, 505 SCID-beige, nude
Thyroid CUTC60 470, 505 SCID-beige, nude
Thyroid CUTC61 470, 505 SCID-beige, nude
Breast BCM-2277 577 nude
Prostate LuCaP-23.1 583 nude
Pancreatic PC13 589 nude
Glioblastoma GBM143 592 nude
Neuroblastoma PC9GR 602 nude
Lung PC9GROR 602 nude
Ovarian OVCAR-5 610 nude
Pancreatic PDX 613 nude
Esophageal squamous cell carcinoma PDX 650 B-NDG
Brain GBM38-Luc-GFP 657 C.B-17 SCID
Brain 15-037 (GBM PDX) 658 C.B-17 SCID
Breast TNBC (KRAS WTPDX) 659 C.B-17 SCID
Prostate (PDX) 675 NOD.SCID
Endometrial (PDX) 681 SCID-beige
Breast BCM-4664 683 SCID-beige
Breast HCI-002 683 SCID-beige
Breast BCM-5471 683 SCID-beige
Breast BCM-2665 683 SCID-beige
Breast BCM-3204 683 SCID-beige
Breast BCM-3107 683 SCID-beige
Breast HMCC-3186 683 SCID-beige
Breast BCM-3936 683 SCID-beige
Breast BCM-4913 683 SCID-beige
Breast HMCC-3555 683 SCID-beige
Ovarian PM-LGSOC-01 684 SCID-beige
Breast WHIM16 685 SCID-beige
Ovarian PH450 687 SCID-beige
Ovarian PH578 687 SCID-beige
Breast WHIM2 (basal-like) 689 SCID-beige
Breast WHIM14 (basal-like) 689 SCID-beige
Rodent Tissue
Bladder (rat) NBT-II 299 nude nude
Bladder AY-27 357 Fischer 344
Brain RT2-GFP 356 Fischer 344
Brain Tu-2449 365 B6C3F1
Brain (murine glioblastoma) GL-261 424 C57BL/6
Brain (murine glioma) RG2 528 RAG2 KO(SD)
Brain (rat glioma) C6 58, 59, 78, 140, 180 NOD.SCID, nude
Breast 4T1-luc2 366, 423, 634 BALB/c
Breast 4T1 379, 381, 382, 390, 473, 477, 627, 635, 636, 637, 639, 640 BALB/c, SCID-beige, NOD.SCID
Breast T11 473 SCID-beige
Breast 67NR 473 SCID-beige
Breast JC 384 C57BL/6J, BALB/c
Breast MMTV-PyMT 418, 673 nude, NOD.SCID
Breast P53-null MECs 390 BALB/c
Breast 4T07 403, 473 BALB/c, SCID-beige
Carcinoma B4B8 388 BALB/c
Carcinoma LY2 388 BALB/c
Carcinoma (murine mammary) 4T1 472 SCID-beige, BALB/c
Carcinoma (murine) LL/2 472 SCID-beige
Carcinoma (murine) KIL C.2 532 B-NDG
Colon AOM-induced colon tumors 358, 359, 364 Fischer 344
Colon CT26 367, 369, 380, 383, 386, 391, 635, 638, 639 C57BL/6, BALB/c
Colon CT26CL25 385 BALB/c
Colon CT26 391 BALB/c
Colon C51 mouse colon cancer cells 447 nude
Colorectal AOM-induced colon tumors 362 Fischer 344
Embryo (murine) Src3T3 299 nude nude
Esophageal NMBA-induced esophageal tumors 360, 361 Fischer 344
Liver MC38-Luc1 387 C57BL/6
Lung (murine) LL2 10 nude
Lung Cancer LL 371 C57BL/6
Lymphoma EL4 367, 371 C57BL/6, BALB/c
Lymphoma E.G7-OVA 373 C57BL/6
Lymphoma E.G7 384 C57BL/6J, BALB/c
Mammary MNU-induced mammary tumors 363 Sprague Dawley
Mammary (rat) DMBA-induced rat mammary carcinoma 301 nude
Mammary (rat) 17β-estradiol-induced mammary tumors 355 Brown Norway
Melanoma B16 367, 369, 378, 456 C57BL/6, BALB/c, SCID-beige
Melanoma RBE4 476 NOD.SCID
Melanoma B16-F10 368, 370 C57BL/6
Melanoma B16-OVA 372, 375 C57BL/6
Melanoma B16.OVA 373 C57BL/6
Melanoma B16.F10 375 C57BL/6
Melanoma (murine) B16F10 35, 36, 250, 392 beige-nude-xid, nude
Oral (murine) PCI-13 498 NOD.SCID
Ovarian (rat) PROb 78 nude
Pancreatic Panc02 367, 374, 377 C57BL/6, BALB/c
Prostate Tgfbr2floxE2 376 C57BL/6
Oral (murine) MmuPV1 (papilloma virus) 554 nude
Breast MMTV-PyMT/RANK-/- 557 nude
Fibrosarcoma MCA205 561, 593, 599 nude
Pancreatic Atmfl/fl; LSL-KrasG12D/+; Ptf1aCre/+ (AKC) cells 569 nude
Glioblastoma WT-GBM 596 nude
Fibrosarcoma MCA205-luc 599 nude
Lymphoctye (pro-B cell) Ba/F3 606 nude
Ovarian ID8 610 nude
Glioma BT4C 622 nude
Breast EMT6-LUC 634 BALB/c
Breast 4T1-mCH 639 BALB/c
Mouse mammary adenocarcinoma TS/A 641 BALB/c
Mouse embryonic stem cells induced hematopoietic endothelial cells (iHECs)  648 B-NDG
Fibrosarcoma NIH3T3 ETV6-NTRK3 653 C.B-17 SCID
Oral (murine) MmuPV1 (papilloma virus) 666 nude
Breast EMT6 673 NOD.SCID
Mouse mammary adenocarcinoma AT3 682 SCID-beige
Canine Tissue
Prostate Ace-1 449 nude
Melanoma MDCK 476 NOD.SCID
Melanoma MDCK-II 476 NOD.SCID


References

1. Verhoef, J.J.C. et al., Radiat Oncol, 2, 38 (2007). Netherlands (athymic nude mice )
2. Ponthan, F. et al., Oncol Reports, 10, 1587 (2003). Netherlands (athymic nude rats)
3. Rubenstein, J.L. et al., Neoplasia, 2(4), 306 (2000). North America (athymic nude rats)
4. Plunkett, R.J. et al., J Neurosurg, 90, 1071 (1999). North America (athymic nude rats)
5. Brignole, C. et al., J Natl Cancer Inst, 96, 1171 (2004). Italy (athymic nude mice, SCID-beige mice)
6. Pan, Y. et al., Breast Cancer Res, 8, R63 (2006). North America (athymic nude mice)
7. Sartorius, C.A. et al., Cancer Res, 65(21), 9779 (2005). North America (athymic nude mice)
8. Arteaga, C.L. et al., Cell Growth & Diff, 4, 193 (1993). North America (athymic nude mice)
9. Hardman, E.W. et al., Cancer Cell Intl, 2, 10 (2002). North America (athymic nude mice)
10. Amiekhosravi, A. et al., Thromb Haemost, 90, 549 (2003). North America (athymic nude mice)
11. Dikmen, Z.G. et al., Turk J Med Sci, 35, 65 (2005). North America (athymic nude mice )
12. Richert, M.M. et al., Breast Cancer Res, 7, R819 (2005). North America (athymic nude mice)
13. Burch, S. et al., J Biomedical Optics, 10, 034011-1-13 (2005). North America (athymic nude rats)
14. Blask, D.E. et al., Breast Cancer Res, And Treatment 79, 313 (2003). North America (athymic nude rats)
15. Bäuerle, T. et al., Intl J Oncol, 28, 573 (2006). Germany (athymic nude rats)
16. Prewett, M.C. et al., Clin Cancer Res, 8, 994 (2002). North America (athymic nude mice)
17. Sheng, H. et al., J Clin Invest, 99, 2254 (1997). North America (athymic nude mice )
18. Yang, M. et al., Proc Nat Acad Sci, 102, 6027 (2005). North America (athymic nude mice )
19. Park, B.H. et al., Proc Natl Acad Sci, 98, 2598 (2001). North America (athymic nude mice )
20. Kruskal, J.B. et al., Radiology, 215, 852 (2000). North America (athymic nude mice)
21. Tijink, B.M. et al., J Nucl Med, 47, 1127 (2006). EU (athymic nude mice)
22. Marchal, F. et al., Oncology Reports, 14, 1203 (2005). France (athymic nude rats)
23. Wang, M. et al., World J Gastroenterol, 9(11), 2627 (2003). France (athymic nude rats)
24. Dauchy, R. T. et al., Cancer Letters, 209, 7 (2004). North America (athymic nude rats)
25. Svechnikova, I. et al., Intl J Oncol, 22, 579 (2003). Netherlands (athymic nude rats)
26. Till, H. et al., Surgical Endoscopy, 19, 1483 (2005). Germany (athymic nude rats)
27. Barone, T.A. et al., Blood, 90, 298 (1997). North America (athymic nude rats)
28. Francisco, J.A. et al., Blood, 102, 1458 (2003). North America (SCID mice)
29. Geldhof, A.B. et al., Clin & Experimental Metastasis, 16(5), 447 (1998). North America (ICR-SCID mice)
30. Wang, M. et al., Blood, 109, 5455 (2007). North America (SCID mice)
31. Zou, Y. et al., J Natl Cancer Inst, 90, 1130 (1998). North America (athymic nude mice)
32. Maneckjee, R. and Minna, J.D., Proc Natl Acad Sci, 89, 1169 (1992). North America (athymic nude mice)
33. Weinberg, O.K. et al., Cancer Res, 65, 11287 (2005). North America (athymic nude mice)
34. Boehle, A.S. et al., Intl J Cancer, 94, 420 (2001). Germany (SCID-beige mice)
35. Horton, H.M. et al., Proc Natl Acad Sci, 96, 1553 (1999). North America (athymic nude mice, beige-nude-xid mice)
36. Malafa, M.P. et al., Annals of Surgical Oncol, 9(10), 1023 (2002). North America (athymic nude mice)
37. Bromberg, M.E. et al., Proc Natl Acad Sci, USA 92, 8205 (1995). North America (SCID mice)
38. Modesitt, S.C. et al., Clin Cancer Res, 7,1487 (2001). North America (athymic nude mice)
39. Duyndam, M.C.A. et al., Am J Pathol, 160, 537 (2002). Netherlands (athymic nude mice)
40. Gossmann, A. et al., J Obstetrics and Gynecol, 183, 956 (2000). North America (athymic nude rats)
41. Mahasreshti, P.J. et al., Clin Cancer Res, 7, 2057 (2001). North America (SCID mice)
42. Fukasawa, M. and Murray, K., Clin Cancer Res, 10, 3327 (2004). North America (athymic nude mice)
43. Koehler, J.A. and Drucker, D.J., Diabetes, 55, 1369 (2006). North America (athymic nude mice)
44. Weber, D. et al., Cancer Res, 60, 5284 (2000). North America (athymic nude mice)
45. Boenicke, L. et al., J Mol Med, 81, 205 (2003). Germany (SCID mice)
46. Zhang, X. et al., J Nucl Med, 47, 492 (2006). North America (athymic nude mice)
47. Tuomela, J.M. et al., BMC Cancer, 8, 81 (2008). Germany (athymic nude mice)
48. Srivastava, S.K. et al., Carcinogenesis, 24(10), 1665 (2003). North America (athymic nude mice)
49. Hillman, G.G. et al., Mol Cancer Ther, 3, 1271 (2004). North America (athymic nude mice)
50. Graff, J.R. et al., J Biol Chem, 275, 24500 (2000). North America (athymic nude mice)
51. Gregory, C.W. et al., Cancer Res, 61, 2892 (2001). North America (athymic nude mice)
52. Cabrera, G. et al., Mol Cancer, 5, 32 doi:10.1186/1476-4598-5-32 (2006). North America (athymic nude rats)
53. Adkins, H.B. et al., J Clin Invest, 112, 575 (2003). North America (athymic nude mice)
54. Weydert, C. et al., Mol Cancer Ther, 2, 361 (2003). North America (athymic nude mice)
55. Fu, X, Tao, L and Zhang, X., Cancer Gene Therapy, 14, 480 (2007). North America (athymic nude mice)
56. Sun, L. and Chen, C., J Biol Chem, 272(40), 25367 (1997). North America (athymic nude mice)
57. Sutherland, M.K. et al., mAbs 1(5), 481 (2009). North America (SCID mice)
58. Lai, C.P.K. et al., Cancer Res, 67(4), 1545 (2007). North America (athymic nude mice)
59. Folkins, C. et al., Cancer Res, 69(18), 7243 (2009). North America (athymic nude mice)
60. Ueno, N.T. et al., Cancer Res, 62, 6712 (2002). North America (athymic nude mice)
61. agata, Y. et al., Cancer Cell, 6, 117 (2004). North America (athymic nude mice )
62. Puig, T. et al., Clin. Cancer Res., 15, 7608 (2009). UK (BALB/c nude mice )
63. Liu, Z. et al., Nano Res, 3(3), 222 (2010). North America (athymic nude mice)
64. Chandarlapaty, S. et al., Oncogene, 29, 325 (2010). EU (athymic nude mice)
65. Simons, A.L. et al., Int J Radiat Oncol Biol Phys, 69(4), 1222 (2007). North America (athymic nude mice)
66. Want, D. et al., Clin Cancer Res, 14(19), 6228 (2008). North America (athymic nude mice)
67. LoTempio, M.M. et al., Clin Cancer Res, 11(19), 6994 (2005). North America (athymic nude mice)
68. Barok, M. et al., Mol Cancer Ther, 6(7), 2065 (2007). Netherlands (NMRI nude mice, SCID mice)
69. Tanner, M. et al., Mol Cancer Ther, 3(12), 1585 (2004). Netherlands (NMRI nude mice)
70. Tanner, M. et al., Annals of Oncol, 16, 273 (2005). Netherlands (NMRI nude mice)
71. Lin, L. et al., Neoplasia, 12(1), 39 (2010). North America (athymic nude mice)
72. Moulder, S.L. et al., Cancer Res, 61, 8887 (2001). North America (athymic nude mice)
73. Zhang, X. et al., Clin Cancer Res, 11, 323 (2005). North America (athymic nude mice)
74. Campbell, R.A. et al., Int J Oncol, 28(6), 1409 (2006). North America (athymic nude mice)
75. Chen, H. et al., Blood, 113, 1992 (2009). North America (athymic nude mice)
76. Dingli, D. et al., Clin Cancer Res, 8, 3948 (2002). North America (SCID mice)
77. Chavez-Blanco, A. et al., Cancer Cell Int, 6, 2 (2006). North America (athymic nude mice)
78. Ferretti, S. et al., Neoplasia, 11(9), 874 (2009). EU (athymic nude mice)
79. Heikkilä, J.E. et al., PLoS ONE, 5(1), e8603 (2010). UK (BALB/c nude mice)
80. Xiao, W. et al., Eur J Nucl Med Mol Imaging, 36, 94 (2009). North America (athymic nude mice)
81. Li, L. et al., Clin Cancer Res, 13(7), 2178 (2007). North America (athymic nude mice)
82. Hsu, A.R. et al., J Nucl Med, 48, 445 (2007). North America (athymic nude mice)
83. Chen, X. et al., J Nucl Med, 45, 1776 (2004). North America (athymic nude mice)
84. Menon, C. et al., Am J Physiol Heart Circ Physiol, 24, H317 (2003). North America (athymic nude mice)
85. Ueno, T. et al., Mol Cancer Ther, 5(3), 732 (2006). North America (athymic nude rats)
86. Goyeneche, A.A. et al., Clin Cancer Res, 13(11), 3370 (2007). North America (athymic nude mice)
87. Li, D. et al., Oncogene, 21, 2805 (2002). North America (athymic nude mice)
88. Boehle, A.S. et al., Ann Thorac Surg, 69, 1010 (2000). Germany (SCID-beige mice)
89. Kurdow, R. et al., Ann Thorac Surg, 73, 905 (2002). Germany (SCID-beige mice)
90. Hamblett, K.J. et al., Clin Cancer Res, 10, 7063 (2004). North America (SCID mice)
91. Santin, A.D. et al., Cancer Res, 65(10), 4334 (2005). North America (SCID mice)
92. Nilsson, M.B. et al., J Biol Chem, 282(41), 29919 (2007). North America (SCID mice)
93. Spaeth, E.L. et al., PloS ONE, 4(4), e4992 (2009). North America (SCID mice)
94. Bruckheimer, E.M. et al., Neoplasia, 11(6), 509 (2009). North America (SCID mice, NOD.SCID mice)
95. Nagengast, W.B. et al., J Nucl Med, 48, 1313 (2007). Netherlands (athymic nude mice)
96. Auzenne, E. et al., Neoplasia, 9(6), 479 (2007). North America (athymic nude mice)
97. Rodrigues-Ferreira, S. et al., PLoS ONE, 4(10), e7239 (2009). UK (SCID mice)
98. Houba, P.H.J. et al., British J Cancer, 78(12), 1600 (1998). Netherlands (athymic nude mice)
99. Vingerhoeds, M.H. et al., British J Cancer, 74, 1023 (1996). Netherlands (NMRI nude mice)
100. Le Pimpec-Barthes, F. et al., British J Cancer, 81(8), 1344 (1999). EU (athymic nude rats)
101. Fu, X. et al., Mol Ther, 7(6), 748 (2003). North America (athymic nude mice)
102. Folberg, R. et al., Invest Ophthalmol Vis Sci, 48(7), 2967 (2007). North America (SCID mice)
103. Swami S., et.al., Horm Cancer. 2011 June 1; 2(3): 190-202. North America (athymic nude mice)
104. Kiyama, S. et al., Cancer Res, 63, 3575 (2003). North America (athymic nude mice)
105. Elsadek, B. et al., Prostate Cancer and Prostatic Diseases, 14, 14 (2011). Germany (SCID mice)
106. Sun, S. et al., J Clin Invest, 120(8), 2715 (2010). North America (athymic nude mice)
107. Li, T.H. et al., Nucleic Acids Res, 35(8), 2767 (2007). North America (athymic nude mice)
108. Pan, J. et al., PLoS ONE, 5(10), e13298. doi:10.1371/journal.pone.0013298 (2010). North America (athymic nude mice)
109. Määttä, A.-M. et al., Int J Cancer, 121, 863 (2007). Netherlands (NMRI nude mice)
110. Jarzynka, M.J. et al., Int J Oncol, 28(2), 337 (2006). North America (athymic nude mice)
111. Bruckheimer, E.M. et al., Neoplasia, 11(6), 509 (2009). North America (athymic nude mice, SCID mice, NOD.SCID mice)
112. Yi, J. M. et al., Cancer Res, 68(19), 8094 (2008). North America (SCID mice)
113. Ovalle, S. et al., Int J Cancer, 121, 2140 (2007). Spain (athymic nude mice )
114. Schleup, T. et al., Clin Cancer Res, 15, 181 (2009). North America (athymic nude mice )
115. Orian-Rousseau, V. et al., Int J Cancer, 113, 699 (2005). Germany (SCID-beige mice)
116. Zielske, S.P. et al., Int J Radiat Oncol Biol Phys, 75(3), 843 (2009). North America (athymic nude mice)
117. Kaafarani, I. et al., FASEBJ, 23, doi: 10.1096/fj.08-127852 (2009). France (NMRI nude mice)
118. Koskimaki, J. E. et al., BMC Cancer, 10, 29 (2010). North America (athymic nude mice)
119. Jakubezak, J.L. et al., Cancer Res, 63, 1490 (2003). North America (athymic nude mice)
120. McEarchern, J.A. et al., Clin Cancer Res, 14, 7763 (2008). North America (SCID mice)
121. Kelley, S.K. et al., Br J Pharmacol, 148(8), 1116 (2006). North America (SCID mice)
122. Smrekar, B. et al., Gene Therapy, 10, 1079 (2003). UK; Germany (SCID mice)
123. Tremmel, M. et al., Blood, 114(25), 5236 (2009). Germany (athymic nude mice)
124. Cuesta, Á.M., et al., PLoS ONE, 4(4), e5381. doi:10.1371/journal.pone.0005381 (2009). Spain (athymic nude mice)
125. Pastorino, F. et al., Cancer Res, 63, 86 (2003). Italy (athymic nude mice )
126. Kelly, P. et al., British J Cancer, 103, 232 (2010). UK (SCID mice)
127. Larkin, J.O. et al., Ultrasound Med Biol, 34(3), 406 (2008). UK (MF1 nude mice)
128. Kang, K.S., et al., PLoS ONE 5(4): e10296. doi:10.1371/journal.pone.0010296 (2010). North America (athymic nude mice)
129. Shah, G.V. et al., Endocrine-Related Cancer, 15, 953 (2008). North America (athymic nude mice)
130. Lipnik, K. et al., Virol, 349, 121 (2006). Germany (SCID-beige mice)
131. Agu, C.A. et al., J Gene Med, 8, 229 (2006). Germany (SCID-beige mice)
132. Rhodes, L.V. et al., Breast Cancer Res Treat, 121(2), 293 (2010). North America (SCID-beige mice)
133. Barone, T.A. et al., J Neuro-Oncol, 95(1), 37 (2009). North America (athymic nude rats)
134. Nanda, D. et al., Cancer Res, 61, 8743 (2001). UK (beige-nude-xid mice)
135. Markaverich, B. et al., Eviron Health Perspect,110, 169 (2002). North America (athymic nude mice)
136. Stan, S.D. et al., Cancer Res, 68(18), 7661 (2008). North America (athymic nude mice)
137. Shashkova, E.V. et al., Cancer Res, 68, 5896 (2008). North America (athymic nude mice)
138. Larkin, J.O. et al., Ann Surg, 245(3), 469 (2007). UK (BALB/c nude mice, MF1 nude mice)
139. Loebinger, M.R. et al., Cancer Res, 69(23), 8862 (2009). UK (NOD.SCID mice)
140. Cai, W. et al., J Nucl Med, 48, 304 (2007). North America (athymic nude mice)
141. Squires, M.S. et al., Mol Cancer, 8(2), 324 (2009). UK (BALB/c nude mice)
142. Airoldi, I. et al., PLoS ONE, 4(7), e6119. doi:10.1371/journal.pone.0006119 (2009). Italy (NOD.SCID mice)
143. Lee, F.Y.F. et al., Cancer Chemother Pharmacol, 63, 201 (2009). North America (athymic nude mice, SCID-beige mice)
144. Yang, J. et al., Cancer Cell, 10, 295 (2006). North America (SCID mice)
145. Dauchy, R.T. et al., J Pineal Res, 47, 32 (2009). North America (athymic nude rat)
146. Wu, J. et al., Cancer Res, 71, 2622 (2011). North America (athymic nude rat)
147. Sharma, S. et al., Ejc Supplements, ISSN:13596349, 8(7), 66 (2010). North America (athymic nude mice)
148. Hadaschik, B.A. et al., Cancer Res, 68, 4506 (2008). North America (athymic nude mice)
149. Chadalapaka, G. et al., Cancer Res, 68(13), 5345 (2008). North America (athymic nude mice)
150. Cho, S.D. et al., Mol Pharmacol, 77(3), 396 (2010). North America (athymic nude mice)
151. Jutooru, I. et al., Exp Cell Res, 316(13), 2174 (2010). North America (athymic nude mice)
152. Zawel, L. et al., PNAS, 99(5), 2848 (2002). North America (athymic nude mice)
153. Donawho, C.K. et al., Clin Cancer Res, 13(9), 2728 (2007). North America (athymic nude mice)
154. Rockett, J.C. et al., Br J Cancer, 75(2), 258 (1997). UK (athymic nude mice)
155. Kan, T. et al., Gastroenterol, 136(5), 1689 (2009) North America (athymic nude mice)
156. Zhang, S. et al. Mol Cancer Ther, 11, 108 (2012). North America (athymic nude mice)
157. Zhang, K.-X. et al., Breast Cancer Res Treat, 125, 89 (2011). North America (athymic nude mice)
158. Zhang, K.-X. et al., Breast Cancer Res Treat, 125, 89 (2011). North America (athymic nude mice)
159. Liu, Z. et al., Nano Res, 3, 222 (2010). North America (athymic nude mice)
160. Rimawi, M.R. et al., Clin Cancer Res, 17, 1351 (2011). North America (athymic nude mice)
161. Zhao, Y. et al., Cancer Res, 71, 4585 (2011). North America (athymic nude mice)
162. Scaltriti, M. et al., Mol Cancer Ther, 10, 817 (2011). North America (athymic nude mice)
163. Massey, A.J. et al., Mol Cancer Ther, 9, 906 (2010). Switzerland (athymic nude mice)
164. Maira, S.-M. et al., Mol Cancer Ther, doi:10.1158/1535-7163.MCT-11-0474. Switzerland (athymic nude mice)
165. O'Donovan, N. et al., Invest New Drugs, 29, 752 (2011). UK (BALB/c nude mice)
166. Chao, O. et al., J Med Chem, 52, 7808 (2009). North America (athymic nude mice)
167. Yu, Y.A. et al., Mol Cancer Ther, 8, 141 (2009). North America (athymic nude mice)
168. Haddad, D. et al., J Translational Med, 9, 36 (2011). North America (athymic nude mice)
169. Gourdeau, H. et al., Cancer Chemother Pharmacol, 61, 911 (2008). North America (athymic nude mice)
170. Liu, T.W. et al., Bioconjugate Chem, 22, 1021 (2011). North America (athymic nude mice, athymic nude rats)
171. Alzani, R. et al., Exp Hematol, 38, 259 (2010). Italy (SCID mice)
172. Sehdev, V. et al., Mol Cancer Ther, doi: 10.1158/1535-7163.MCT-11-0623 (2012). North America (athymic nude mice)
173. Bralten, L.B.C. et al., Ann Neurol, 69, 455 (2011). Netherlands (SCID mice)
174. Ayuzawa, R. et al., Cancer Letters,280, 31 (2009). North America (SCID mice)
175. Barok, M. et al., Cancer Letters, 306, 171 (2011). Netherlands (SCID mice)
176. Zeng, Q. et al., Euro J Cancer, 46, 1132 (2010). North America (athymic nude mice)
177. Pais, A. et al. Cancer Res, 71(24), 7387 (2011). Israel (SCID mice)
178. Junttila, T.T. et al., Cancer Cell, 15, 429 (2009). North America (SCID mice)
179. Daigle, S. R. et al., Cancer Cell, 20, 53 (2011). North America (athymic nude mice)
180. Patyna, S. et al. Mol Cancer Ther, 5, 1774 (2006). North America (athymic nude mice, NOD.SCID mice)
181. Zarrinkar, P.P. et al. Blood, 114(14), 2984 (2009). North America (NOD.SCID mice)
182. Mertz, J.A. et al., PNAS, 108(40), 16669 (2011). North America (athymic nude mice)
183. Tokalov, S.V. et al., J Biomed and Biotechnol, Article ID 580531, 4 p doi:10.1155/2010/580531 (2010). Germany (athymic nude rats)
184. Anastas, J.N. et al., Oncogene, doi:10.1038/onc.2011.528 (2011). North America (athymic nude mice)
185. Mitra, A. et al., Breast Cancer Res, 10:R22 (2008). North America (athymic nude mice)
186. Volk, L.D. et al., Neoplasia, 10(6), 613 (2008). North America (athymic nude mice)
187. Hiraga, T. et al., Cancer Res, 61, 4418 (2001). North America (athymic nude mice)
188. Mukhopadhyay, K.D. et al., PLoS ONE, 6(6), e20473 (2011). North America (athymic nude mice)
189. Bandyopadhyay, A. et al., PLoS ONE, 5(4), e10365 (2010). North America (athymic nude mice)
190. Walsh, C. et al., Cancer Biol Ther, 9(10), 778 (2010). North America (athymic nude mice, BALB/c SCID mice)
191. Lee, S.-M. et al., ACS Nano, 4(9), 4971 (2010). North America (athymic nude mice)
192. Kerjaschki, D. et al. J Clin Invest, 121(5), 2000 (2011). Germany (SCID mice)
193. Whitehurst, B. et al., Int J Cancer, 121, 2181 (2007). North America (SCID mice)
194. Graeser, R. et al., Int J Cancer, 122, 1145 (2008). Germany (SCID mice)
195. Gomez-Manzano, C. et al., Neuro-Oncol, 10, 940 (2008). North America (athymic nude mice)
196. et al., Cancer Gene Ther, 12, 947 (2005). Germany (athymic nude mice)
197. Verheije, M.H. et al., J Virol, 83(15), 7507 (2009). Netherlands (athymic nude mice)
198. Ke, L.D. et al., Clin Cancer Res, 6, 2562 (2000). North America (athymic nude mice)
199. Clark, A.J. et al., J Neurosurg, 112, 18 (2010). North America (athymic nude mice)
200. Calzolari, A. et al., Transl Oncol, 3(2), 123 (2010). Italy (athymic nude mice)
201. Schiappacassi, M. et al., Mol Cancer Ther, 7(5), 1164 (2008). Italy (athymic nude mice)
202. Yoon, H. et al., J Cellular Biochem, 108, 832 (2009). North America (athymic nude mice)
203. Abourbeh, G. et al., Nucl Med and Biol, 34, 55 (2007). Israel (athymic nude mice)
204. Benny, O. et al., FASEB J, 22, 488 (2008). Israel (CD-1 nude mice)
205. Yin, S. et al., Neuro-Oncol, 12(1), 19 (2010). Sweden (athymic nude rats)
206. Khan, Z. et al., Neuro-Oncol, 12(6), 549 Sweden (athymic nude rats)
207. Buursma, A.R. et al., J Nucl Med, 46, 2068 (2005). Netherlands (athymic nude rats)
208. Gunasekaran, K. et al., J Biol Chem, 285(25), 19637 (2010). North America (NOD.SCID mice)
209. Li, J.-L. et al., Cancer Res, 67(23), 11244 (2007). Germany (BALB/c SCID mice)
210. Holen I., et.al., Breast Cancer Research 2012, 14:R86. United Kingdom (BALB/c nude mice)
211. Hennessy, B.T. et al. Clin Cancer Res, 13(24), 7421 (2007). North America (athymic nude mice)
212. Nakamori, M. et al., 9, 2727 (2003). North America (athymic nude mice)
213. Ma, L. et al., Acta Biochim Biophys Sin, 42(9), 593 (2010). Asia (BALB/c nude mice)
214. Shao, M. et al., Cancer Res, 69, 9192 (2009). North America (BALB/c nude mice)
215. Lljin, K. et al., Clin Cancer Res, 15(19), 6070 (2009). Finland (athymic nude mice)
216. Izhak, L. et al., J Immunol, 183, 732 (2009). Israel (SCID-beige mice)
217. Inbar-Rozensal, D. et al., Breast Cancer Res, 11, R78 (2009). Israel (CD-1 nude mice)
218. González, L. et al., J Biol Chem, 281(30), 20851 (2006). Spain (athymic nude mice)
219. Wu, L. et al., Clin Cancer Res, 11(22), 8195 (2005). North America (athymic nude mice)
220. Ghosh, A.K. et al., Cancer Res, 56(3), 718 (2005). North America (athymic nude mice)
221. Tang, L. et al., J Nutr, 135, 287 (2005). North America (athymic nude mice)
222. Fu, X. et al., Gene Ther, 10, 1458 (2003). North America (athymic nude mice)
223. Shashkova, E.V. et al., Cancer Res, 68(14), 5896 (2008). North America (athymic nude mice)
224. Ozawa, T. et al., Mol Pharmaceutics, 1(5), 368 (2004). North America (athymic nude rats)
225. Bristol, J.A. et al., Mol Ther, 7(6), 755 (2003). North America (athymic nude mice)
226. Folgiero, V. et al., Cell Death and Disease, 3, e440; doi:10.1038/cddis.2012.179 (2012). Italy (athymic nude mice, SCID mice)
227. Jensen, M.R. et al., Breast Cancer Res, 10, R33 (2008). Switzerland (athymic nude mice)
228. Golubovskaya, V.M. et al., J Med Chem, 51(23), 7405 (2008). North America (athymic nude mice)
229. Hernandez-Alcoceba, R. et al., Human Gene Ther, 11, 2009 (2000). North America (athymic nude mice)
230. Gutierrez, M.C. et al., JCO, 23(11), 2469 (2005). UK (athymic nude mice)
231. Mahller, Y.Y. et al. PLoS ONE, 4(1):e4235. doi:10.1371/journal.pone.0004235 (2009). North America (athymic nude mice)
232. Zhou, Y. et al., J Biol Chem, 286, 32843 (2011). North America (athymic nude mice)
233. Salvatori, L. et al., PLoS ONE, 7(2), e31467. doi:10.1371/journal.pone.0031467 (2012). Italy (NOD.SCID mice)
234. Londoño-Joshi, A.I. et al., Breast Cancer Res Treat, DOI 10.1007/s10549-011-1763-0 (2011). North America (NOD.SCID mice)
235. Joseph, I. et al., Cancer Res, 70, 9494 (2010). North America (athymic nude mice)
236. Lonardo, E. et al., Cell Stem Cell, 9(5), 433 (2011). Spain (athymic nude mice)
237. Xiao, K. et al., Biomaterials, 30(30), 6006 (2009). North America (athymic nude mice)
238. Li, Y. et al., J Immunol, 179, 4263 (2007). North America (SCID mice)
239. Kumagai, T. et al., J Natl Cancer Inst, 95(12), 896 (2003). North America (beige-nude-xid mice)
240. Kumagai, T. et al., Clin Cancer Res, 10, 1508 (2004). North America (beige-nude-xid mice)
241. Audo, I. et al., Invest Ophthalmol Vis Sci, 44, 4192 (2003). North America (athymic nude mice)
242. Cocco, C. et al., Clin Cancer Res, 16, 4188 (2010). Italy (NOD.SCID mice)
243. Ayers, G.D. et al., J Ultrasound Med, 29(6), 891 (2010). North America (athymic nude mice)
244. Ning, S. et al., Cancer Res, 70(19), OF1 (2010). North America (athymic nude rats)
245. Yee, A.J.M. et al., Breast Cancer Res, 9(4), R47 (2007). North America (CD-1 nude mice, athymic nude rats )
246. Mercatelli, N. et al., PLoS ONE, 3(12), e4029 (2008). Italy (SCID mice)
247. Thallinger, C. et al., J Invest Dermatol, 127, 2411 (2007). Germany (SCID mice)
248. Elsner, L. et al., J Immunol, 179, 5523 (2007). Germany (SCID-beige mice)
249. Ren, G. et al., J Nucl Med, 50, 1692 (2009). North America (athymic nude mice)
250. Morello, S. et al., Neoplasia, 13(4), 365 (2011). Italy (athymic nude mice)
251. Stangl, S. et al., J Immunol, 176, 6270 (2006). Germany (SCID-beige mice)
252. Phillips, G.D.L. et al., Cancer Res, 68, 9280 (2008). North America (beige-nude-xid mice)
253. Lee-Hoeflich, S.T. et al., Cancer Res, 68, 5878 (2008). North America (beige-nude-xid mice)
254. Yao, E. et al., Clin Cancer Res, 15, 4147 (2009). North America (beige-nude-xid mice)
255. Allegrucci, C. et al., Mol Cancer, 10, 7 (2011). UK (MF1 nude mice)
256. Brachmann, S.M. et al., PNAS, 106(52), 22299 (2009). North America (athymic nude mice)
257. Hoeflich, K.P. et al., Clin Cancer Res, 15(14), 4649 (2009). North America (beige-nude-xid mice)
258. Wong, T.W. et al., Clin Cancer Res, 12(20), 6186 (2006). North America (athymic nude mice)
259. Halasi, M. et al., Cell Cycle, 9(4), 1214 (2010). North America (athymic nude mice)
260. Zhang, S. et al., Endocrine-Related Cancer, 16, 835 (2009). North America (athymic nude mice)
261. Hitosugi, T. et al., Mol Cell, 44(6), 864 (2011). North America (athymic nude mice)
262. Jimeno, A. et al., Cancer Res, 65, 3003 (2005). North America (athymic nude mice)
263. Mutsaers, A.J. et al., Clin Cancer Res, 15, 2397 (2009). North America (athymic nude mice)
264. Guix, M. et al., J Clin Invest, 118(7), 2609 (2008). North America (athymic nude mice)
265. Donnini, S. et al., Oncogene, doi:10.1038/onc.2011.503 (2011). Italy (athymic nude mice)
266. Shir, A. et al., Clin Cancer Res, 17, 1033 (2011). Israel (NOD.SCID mice)
267. Lee, C.M. et al., BMC Cancer, 10, 255 (2010). North America (athymic nude mice)
268. Alameda, J.P. et al., Cell Death and Disease, 2, e208; doi:10.1038/cddis.2011.82 (2011). Spain (athymic nude mice)
269. Valle BL, et al,. PLoS ONE 8(4): e61836 (2013). North America (athymic nude mice)
270. Zhang C.C, et.al., Clinical Cancer Research 1-12; 2012. AACR. France (athymic nude mice)
271. Carlson B. L, et.al., Curr Protoc Pharmocol. 2011 mar; Chapter 14: Unit 14. 16 (2011). North America (athymic nude mice)
272. Calles A., et.al., Curr Protoc Pharmacol. 2013 Jun; Chapter 14: Unit 14.26 (2013). North America (NOD.SCID mice, athymic nude mice)
273. Litzenburger BC., et.al., Clin Cancer Res April 15, 2011. 17; 2314. North America (NOD.SCID mice)
274. Schott AF, et.al., Clin Cancer Res clincanres.3326.2012; Published Online First January 22, 2013. North America (SCID-beige mice)
275. Leake K, et.al., PLoS ONE 7(4): e34582 (2012). North America (athymic nude mice)
276. Zhao S, et.al., Oncogenesis (2013) 2, e76. North America (athymic nude mice)
277. Hernandez JL, et.al., PLoS ONE 8(9): e72480 (2013). Spain (athymic nude mice)
278. Jager W, el.al., PLoS ONE 8(3): e59536 (2013). North America (athymic nude mice)
279. Shin D.H, et.al., JNCI J Natl Cancer Inst (2013). North America (athymic nude mice)
280. Venkatasubbarao K, et.al., Molecular Cancer 2013, 12:104. North America (athymic nude mice)
281. Rybczynska A.A, el.al., J Nucl Med September 1, 2013. The Netherlands (athymic nude mice)
282. Gholami S, et.al., Breast Cancer Research 2013, 15:R26. North America (athymic nude mice)
283. Zins K, et.al., Mol. Sci. 2013, 14, 17958-17971. Germany (athymic nude mice)
284. Benavente S, et.al., Clin Cancer Res March 1, 2009 15; 1585. North America (athymic nude mice)
285. Verhoeff JJC, et.al., Radiation Oncology 2007, 2:38. The Netherlands (athymic nude mice)
286. Alessandro GD, et.al., Cell Death and Disease (2013) 4, e773. Italy (C.B-17 SCID mice)
287. Jiang J., et.al., Oncol Rep. 2012 October; 28(4): 1139-1145. North America (athymic nude mice)
288. Koht HE., et.al., The Journal of Clinical investigation. Volume 122, number 3, March 2012. North America (athymic nude mice)
289. Barok M., et.al., Breast Cancer Research 2011, 13:R46. The Netherlands (C.B-17 SCID mice)
290. Thorner Ar., et.al., PLoS ONE 5(10)e13073. North America (athymic nude mice)
291. Hamada K., et.al., Gynecologic Oncology 99 (2005) S159-S165. North America (athymic nude rats)
292. Lheureux S., et.al. Transl Oncol. 2013 October; 6(5): 586-595. North America (athymic nude rats)
293. Millar HJ., et.al., Cancer Epidemiol Biomarkers Prev August 2008 17; 2180. North America (athymic nude rats)
294. Ayers GD., et.al., JUM June 1, 2010 vol. 29 no. 6 891-90. North America (athymic nude mice)
295. Cyran CC., et.al., PLoS ONE 8(9): e76009. North America (athymic nude rats)
296. Daigle SR., et.al., Blood 2013 122: 1017-1025. North America (athymic nude rats)
297. Jafri SH., et al., Journal of Experimental & Clinical Cancer Research 2010 29:87. North America (C.B-17 SCID mice)
298. Dingli D., et al., Blood 2003 102: 489-496. North America (C.B-17 SCID mice)
299. Green TP., et.al., Molecular Oncology 3 (2009), 248-261. France (athymic nude mice)
300. Kreider JW., at al., Cancer Research 39, 273-276, January 1979. North America (athymic nude mice)
301. Welsch CW, et.al, JNCI J Natl Cancer Inst (1987) 78 (3): 557-565. North America (athymic nude mice)
302. Park SI., et.al., Curr Protoc Pharmacol. 2010 December 1; 51: 14.15-14.15.27. North America (athymic nude mice)
303. Fernandes MS., et.al., Clin Cancer Res August 1, 2009 15; 4847. North America (C.B-17 SCID mice)
304. Mundra JJ., et.al, JPET August 2012 vol. 342 no. 2 273-287. North America (SCID mice)
305. Peng KW., et.al., Blood, 1 October 2001. Vol. 98. Numb. 7. North America (C.B-17 SCID mice)
306. Bhatia N., et.al., J Invest Dermatol. 2013 March ; 133(3): 759-767. North America (athymic nude mice)
307. Mischek D., et.al., Journal of Biomedicine and Biotechnology, Volume 2009 (2009), Article ID 437284. Germany (SCID-beige mice)
308. Harrell JC., et.al., Cancer Res September 15, 2006 66; 9308. North America (athymic nude mice)
309. Kumar S., et.al., Am J Pathol. 2003 December; 163(6): 2531-2541. North America (athymic nude mice)
310. Schafer JM., et.al., Clin Cancer Res November 2000 6; 4373. North America (athymic nude mice)
311. Gottardis MM., et.al., J Steroid Biochem. 1988;30(1-6):311-4. North America (athymic nude mice)
312. O’Regan RM., et. al., JNCI J Natl Cancer Inst (2002) 94 (4): 274-283. North America (athymic nude mice)
313. Morrison MM., J Clin Invest. 2013;123(10):4329-4343. North America (athymic nude mice)
314. Suhong Xiao, et.al., The Journal of Biological Chemistry, 287, 12559-12577. North America (athymic nude mice, beige-nude-xid mice, SHrN® mice)
315. Nguyen N, et.al., Cancer Prev Res. February 2011 4; 248. North America (athymic nude mice)
316. Wang S, at.al., Cancer Gene Therapy (2002) 9, 1-8. doi:10.1038/sj.cgt.7700402. North America (athymic nude mice)
317. Mathieu V.et.al, Oncotarget. Apr 2012; 3(4): 399-413. Germany (BALB/c SCID mice)
318. Vaha-Koskela MJV., et.al., Cancer Res July 15, 2006 66; 7185. The Netherlands (SCID mice)
319. Thallinger C., et.al., Journal of Investigative Dermatology (2003) 120, 1081-1086; doi:10.1046/j.1523-1747.2003.12252.x. Germany (C.B-17 SCID mice)
320. Mathieu MG., et.al., Cell Death and Disease (2014) 5, e1061; doi:10.1038/cddis.2014.29 Published online 13 February 2014. United Kingdom (NOD.SCID mice)
321. Hafner C., et.al., Int. J. Cancer: 114, 426-432 (2005). Germany (C.B-17 SCID mice)
322. Luciani F, et.al., Oxford Journals Medicine JNCI J Natl Cancer Inst Volume 96, Issue 22 Pp. 1702-1713. Italy (C.B-17 SCID mice)
323. Ong C.C., et.al., JNCI J Natl Cancer Inst (2013) djt054 doi: 10.1093/jnci/djt054. North America (beige-nude-xid mice)
324. Lotan T., et.al., Cancer Res. Apr 1, 2008; 68(7): 2166-2175. North America (beige-nude-xid mice)
325. Goel A., et.al., Blood 2007 110: 2342-2350. North America (beige-nude-xid mice)
326. Zeng Y, et.al., J Biol Chem. Apr 22, 2011; 286(16): 13985-13994. North America (C.B-17 SCID mice)
327. Hofmann M., et.al., Neoplasia (New York, N.Y.) (Impact Factor: 5.48). 09/2009; 11(8):812-22. Germany (NOD.SCID mice)
328. Wang L., et.al., J Clin Neurosci. Jun 2012; 19 (6): 881-883. North America (NOD.SCID mice)
329. Sharad S. Singhal, et.al., Cancer Res. May 15, 2009; 69(10): 4244-4251. North America (athymic nude mice)
330. Amornphimoltham P., et.al., Clin Cancer Res. Mar 15, 2013; 19(6): 1375-1388. North America (athymic nude mice)
331. Ricci-Vitiani L., et.al., Cell Death and Differentiation (2008) 15, 1491-1498; doi:10.1038/cdd.2008.72; published online 23 May 2008. Italy (athymic nude mice)
332. Chiron M., et.al., Mol Cancer Ther June 2014 13; 1636. France (NMRI nude mice)
333. Presnell SC., et.al., Am J Pathol. Sep 2001; 159(3): 855-860. North America (athymic nude mice)
334. Stebbing J., et.al., Cancer. Volume 120, Issue 13, pages 2006-2015, 1 July 2014. North America (athymic nude mice)
335. Weekes CD., et.al., Neoplasia. Aug 2012; 14(8): 69-701. North America (athymic nude mice)
336. Pitts TM, et al., (2014) PLoS ONE 9(11): e113037. doi:10.1371/journal.pone.0113037. North America (athymic nude mice)
337. Toussaint G.L., et.al., Molecular Cancer 2012, 11:32. North America (athymic nude mice)
338. Bradshaw-Pierce E.L., et.al., Front. Pharmacol., 22 March 2013 | doi: 10.3389/fphar.2013.00022. North America (athymic nude mice)
339. Petit V., et.al., Laboratory Investigation (2013) 93, 611-621; doi:10.1038/labinvest.2013.44; published online 4 March 2013. France (BALB/c nude mice)
340. Anne L van de Ven, et.al., New Journal of Physics 15 (2013) 055004. North America (SCID-beige mice)
341. Tchoghandjian A., et.al., Cell Death & Differentiation 21, 735-747 (May 2014). France (athymic nude mice)
342. Veeravagu A., et.al., Clin Cancer Res November 15, 2008 14; 7330. North America (athymic nude mice)
343. Mei J., et.al., Mol Cell Biol. Sep 2011; 31(7):3584-3592. North America (NOD.SCID mice)
344. Wang J., et al., Cancer Cell 12, 239-251, September 2007. North America (athymic nude mice)
345. Chisholm EJ., et.al., Cancer Res March 15, 2009 69; 2655. United Kingdom (BALB/c nude mice)
346. Gao Z., et.al., International Journal of Cancer Volume 82, Issue 3, pages 346-352, 30 July 1999. North America (athymic nude mice)
347. Dauchy RT., et.al., Comparative Medicine. Vol. 62, No 2, April 2012, pages 99 - 108. North America (athymic nude rats)
348. Diagle SR., et.al., Blood: 122 (6). August 8, 2013. North America (athymic nude rats)
349. Serra V, et.al., J Clin Invest. 2013;123(6):2551-2563. Spain (athymic nude mice, NMRI nude mice)
350. Nephew KP., et. al., Cancer Res Published OnlineFirst July 17, 2014. North America (athymic nude mice)
351. Pirazzoli V., et.al., Cell Reports 7, 999-1008, May 22, 2014. North America (athymic nude mice)
352. Garcia R.R., et.al., Am J Clin Exp Urol 2014;2(1):82-91. North America (athymic nude mice)
353. Nofiele JT., et.al., PLoS ONE 9(5): e97950. North America (athymic nude rats)
354. Kolev, V.N., et al., Cancer Res January 15, 2015 75; 446. North America (SHrN™ mice, NOD.SCID mice)
355. Colletti, JA II et al. G3 (Bethesda). 4 (2014) 1385-1394. North America (Brown Norway rats)
356. Munson, JM., et al. Cancer Res. 73 (2013) 1536-1546. Swtizerland (Fisher 344 rats)
357. Bhattacharya, A., et al. Carcinogenesis. 34 (2013) 2593-2599. North America (Fisher 344 rats)
358. Janakiram, NB., et al., Cancer.Prev.Res.(Phila). 6 (2013) 1251-1261. North America (Fisher 344 rats)
359. Ravillah, D., et al. et al., J.Pharmacol.Exp.Ther. 348 (2014) 59-68. North America (Fischer 344 rats)
360. Shi, N., et al. Oncotarget. 5 (2014) 11333-11344. North America (Fischer 344 rats)
361. Yang, L., et al., Int.J.Biochem.Mol.Biol. 3 (2012) 46-57. China (Fischer 344 rats)
362. Stypula-Cyrus, Y., et al., FEBS Lett. 588 (2014) 829-835. North America (Fischer 344 rats)
363. Khazal, KF., et al. Anticancer Res. 33 (2013) 1519-1523. North America (Spraque Dawley rats)
364. Ouyang, N., et al. Int.J.Oncol. 42 (2013) 643-650. North America (Fischer 344 rats)
365. Ostertang D., et.al., Neuro Oncol. 2012 February; 14(2): 145–159. North America (B6C3F1 mice)
366. Rashid OM., et.al., Journal of Thoracic Disease. Vol 5, No 4 (August 2013). North America (BALB/c mice)
367. Anz, D., et al, Int.J.Cancer 129 (2011) 2417-2426. Germany (C57BL/6 mice; BALB/c mice)
368. Barbieri, A., et al, J.Cell.Mol.Med. 16 (2012) 920-926. Italy (C57BL/6 mice)
369. Adinolfi, E., et al. Cancer Res. 72 (2012) 2957-2969. Italy (C57BL/6 mice; BALB/c mice)
370. Gurzov, EN., et al. Oncogene 27 (2008) 641-652. Spain (C57BL/6 mice)
371. Basile, LA., et al. J.Transl.Med. 6 (2008) 26-5876-6-26. North America (C57BL/6 mice)
372. Balkow, S., et al, Exp.Dermatol. 18 (2009) 78-87. Germany (C57BL/6 mice)
373. Llopiz, D., et al, Int.J.Cancer 125 (2009) 2614-2623. Spain (C57BL/6 mice)
374. Jacobs, C., et al, Int.J.Cancer 128 (2011) 897-907. Germany (C57BL/6 mice)
375. Aranda, F., et al, Cancer Res. 71 (2011) 3214-3224. 2011. Spain (C57BL/6 mice)
376. Li, X., et al, Oncogene 27 (2008) 7118-7130. North America (C57BL/6 mice)
377. Spitzer, D., et al, Cancer Res. 72 (2012) 201-209. North American (C57BL/6 mice)
378. Uluckan, MC., et al, J.Cell.Biochem. 104 (2008) 1311-1323. North American (C57BL/6 mice)
379. Bandyopadhyay, A., et al. PLoS One 5 (2010) e10365. North America (BALB/c mice)
380. Cambien, B., et al, PLoS One 6 (2011) e28842. France (BALB/c mice)
381. Cooney, CA., et al, Breast Cancer Res. 13 (2011) R58. North America (BALB/c mice)
382. Israyelyan, A., et al. Virol.J. 5 (2008) 68-422X-5-68. North America (BALB/c mice)
383. Jungwirth, U., et al. et al, Mol.Pharmacol. 81 (2012) 719-728. Austria (BALB/c mice)
384. Lapteva, N., et al. J.Immunother. 32 (2009) 145-156. North America (BALB/c mice, C57BL/6J mice)
385. Mojic, M., et al. Mol.Pharmacol. 82 (2012) 700-710. Serbia (BALB/c mice)
386. Qiao, Y., et al. Oncotarget 2 (2011) 59-68. North America (BALB/c mice)
387. Vanrell, L., et al, Mol.Ther. 19 (2011) 1245-1253. Spain (BALB/c mice)
388. Vigneswaran, N. et al. Exp.Mol.Pathol. 90 (2011) 215-225. North America (BALB/c mice)
389. Walsh, C., et al, Cancer.Biol.Ther. 9 (2010) 778-790. North America (BALB/c mice)
390. Zhang, M., et al, Cancer Res. 68 (2008) 4674-4682. North America (BALB/c mice)
391. Zigmond, E., et al. PLoS One 6 (2011) e28858. Israel (BALB/c mice)
392. Ganesh, S., et al. Mol Cancer Ther (2016) Jul 7. North America (athymic nude mice)
393. Jiménez-Valerio, G. et al. Cell Rep. (2016) May 10; 15(6):1134-43. Spain (athymic nude mice)
394. Zhao, S., et al., Clin Cancer Res. (2016) Jun 7. North America (athymic nude mice)
395. Francis, DM., et al. Clin Cancer Res. (2016) Feb 1; 22(3):633-43. North America (athymic nude mice)
396. Crottès D., et al. Cancer Res. 2016 Feb 1; 76(3):607-18. France (SHrN™ mice)
397. Kathagen-Buhmann A., et al. Neuro Oncol. 2016 Feb 24. Germany (SHrN™ mice)
398. Jones R.J., et al. Clin Cancer Res. 2016 Jun 13. North America (C.B-17 SCID mice)
399. Alagpulinsa D.A., et al. Mol Cancer Ther. 2016 Feb; 15(2):241-50. North America (C.B-17 SCID mice)
400. Halle B., et al. J Neurooncol. 2016 Jan; 126(1):47-55. Denmark (athymic nude rats)
401. Debeb B.G., et al. J Natl Cancer Inst. 2016 Apr 13; 108(8). North America (SCID-beige mice)
402. Hudson K., et al. Mol Cancer Ther. 2016 May; 15(5):877-89. United Kingdom (SCID-beige mice)
403. Gravekamp, C., et al. (2004). Experimental Biology and Medicine, 229(7), 665-675. North America (BALB/c mice)
404. Toussaint, M., et al. Theranostics, 2017; 7(2): 436-451. France (athymic nude rat)
405. Li, R., et. al, Current Cancer Drug Targets, 2014, 14, 274-285. China (athymic nude mouse)
406. Schoenfeld, J.D., et al. Redox Biol. 2018 Apr;14:417-422. North America (athymic nude mouse)
407. Sciegienka S.J., et al. Free Radic Biol Med. 2017 Jul;108:354-361. North America (athymic nude mouse)
408. Segatto, I., et al. Aging, 8(5), 958-976. United Kingdom (athymic nude mouse)
409. Sen, T., et al. Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, 2017 23(20), 6239-6253. North America (athymic nude mouse)
410. Shao, C., et al. J Biol Chem. 2015 Jan 23;290(4):2024-33. North America (athymic nude mouse)
411. Stafman, L.L., et al. Oncotarget. 2018 Apr 27; 9(32): 22665–22679. North America (athymic nude mouse)
412. Tan Q., et al. Br J Cancer. 2015 Mar 3; 112(5): 832–840. North America (athymic nude mouse)
413. Toden S., et al. Oncotarget. 2016 Mar 29; 7(13): 16158–16171. North America (athymic nude mouse)
414. Wang W., et al. J Neurosurg. 2018 Mar;128(3):695-700. North America (athymic nude mouse)
415. Waters A.M., et al. Mol Cancer Ther. 2016 May; 15(5): 911–921. North America (athymic nude mouse)
416. Yan H., et al. Oncotarget. 2016 Jul 12; 7(28): 43352–43362. North America (athymic nude mouse)
417. Yan S.B., et al. Invest New Drugs. 2018; 36(4): 536–544. North America (athymic nude mouse)
418. Yeo S.K., et al. Cancer Res. 2016 Jun 1; 76(11): 3397–3410. North America (athymic nude mouse)
419. Zumwalt T.J., et al. Cancer Prev Res (Phila). 2017 Mar; 10(3): 208–218. North America (athymic nude mouse)
420. Alexander M.S., et al. Cancer Res. 2018 Sep 25. pii: canres.1680.2018. North America (athymic nude mouse)
421. Choi A.H., et al. Surgery. 2018 Feb;163(2):336-342. North America (athymic nude mouse)
422. Donabedian P.L., et al. EJNMMI Res. 2018; 8: 59. North America (athymic nude mouse)
423. Nguyen O.N., et al. Cancer Res. 2017 Mar 15;77(6):1427-1438. Europe (BALB/c mice)
424. Barrett, J. A., et al. 2018. Cancer Gene Therapy, 25(5-6), 106-116. North American (C57BL/6 mice)
425. Thisgaard, H., et al. 2016. Theranostics, 6(12), 2278-2291. Denmark (athymic nude rats)
426. Buck, J. R., et al. 2015. PloS One, 10(10), e0141659. North America (athymic nude rats)
427. Gruslova, A., 2015. Journal of Neuro-Oncology, 124(3), 365-372. North America (athymic nude rats)
428. Qureshi-Baig, K., 2016. PloS One, 11(1), e0146052. Europe (NOD.SCID mice)
429. Torres-Guzman, R., et al. 2017. Oncotarget, 8(41), 69493-69507. North America (NOD.SCID mice)
430. Zhang, Y., et al. 2018. Nature Communications, 9(1), 4080-018-06177-2. North America (NOD.SCID mice)
431. Banerjee, K., et al. 2018. Clinical Oncology and Research, 1(1). North America (NOD.SCID mice)
432. Frosina, G., et al. 2018. Scientific Reports, 8(1), 14191-018-32578-w. Europe (NOD.SCID mice)
433. Gross, A. C., et al. 2018. JCI Insight, 3(16), 10.1172/jci.insight.99791. North America (C.B-17 SCID mice)
434. Kryeziu, K., et al. 2016. Oncotarget, 7(19), 27379-27393. Europe (C.B-17 SCID mice)
435. Ryan, M. C., et al. 2017. Blood, 130(18), 2018-2026. North America (C.B-17 SCID mice)
436. Abrams, T., et al. 2018. Clinical Cancer Research, 24(17), 4297-4308. North America (SCID-beige mice)
437. Butler, K. A., et al. 2017. Neoplasia (New York, N.Y.), 19(8), 628-636. North America (SCID-beige mice)
438. Gill, S. E., et al. 2017. Oncotarget, 8(49), 85214-85223. North America (SCID-beige mice)
439. Goncalves, A. F., et al. 2017. Nature Communications, 8(1), 1466-017-01514-3. Europe (SCID-beige mice)
440. Park, J. H., et al. 2016. Cell Reports, 14(9), 2154-2165. North America (SCID-beige mice)
441. Debeb, B. G., et al. 2016. Journal of the National Cancer Institute, 108(8). North America (SCID-beige mice)
442. Song, W., et al. 2017. Oncogene, 36(40), 5620-5630. North America (NOD.SCID mice)
443. Williams, A. P., et al. 2018. Translational Oncology, 12(1), 84-95. North America (athymic nude mouse)
444. Yu, X., et al. 2018. International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology, 47(3), 957-971. Asia (athymic nude mouse)
445. Ziegler, J., et al. (2017). Oncotarget, 8(42), 71833-71844. North America (athymic nude mouse)
446. Van de Sande, L., et al. (2019). BMC Cancer, 19(1), 424. Belgium (athymic nude rats)
447. Grünewald, S., et al. (2019). Int J Cancer, 145(5), 1346-1357. Germany (athymic nude rats)
448. Owonikoko, T.K., et al. (2019). PLoS One, 14(2), e0206309. North America (athymic nude rats)
449. Atkins, A., et al. (2019). Ann Biomed Eng, 47(4), 980-989. Canada (athymic nude rats)
450. Vermandel, M., et al. (2019). Photodiagnosis Photodyn Ther, 25, 166-176. France (athymic nude rats)
451. Vega, F.M., et al. (2019). EBioMedicine, 49, 82-95.Spain (CB-17 mice)
452. Wang, Y., et al. (2019). Mol Cancer Ther, 19(2), 364-374. North America (CB-17 mice)
453. Nguyen, T., et al. (2019). Cell Rep, 27(2), 491-501.e6 North America (CB-17 mice)
454. Pfitzer, L., et al. (2019). Cell Death Dis, 10(4), 302. Germany (CB-17 mice)
455. Fonti, C., et al. (2019). Int J Cancer, 145(5), 1299-1311. France (SCID-beige mice)
456. Felder, M., et al. (2019). Gynecol Oncol, 152(3), 618-628 North America (SCID-beige mice)
457. Torres, D., et al. (2019). PLoS One, 4(11), e0224564. North America (SCID-beige)
458. Santiago-O'Farrill, J.M., et al. (2020). Bast RC Jr. Cancer, 126(4), 894-907. North America (SCID-beige)
459. McDaid, W.J., et al. (2019). Nanoscale, 11(42), 20261-20273. UK (SCID-beige)
460. Kanakkanthara, A., et al. (2019). Nat Commun, 10(1), 4632. North America (SCID-beige)
461. Le Joncour, V., et al. (2019). Mol Cancer Ther, 18(10), 1721-1730. Finland (SCID-beige)
462. Guerra-Rebollo, M., et al. (2019). Sci Rep, 9(1), 9549. Spain (SCID-beige)
463. Owonikoko, T.K., et al. (2019). PLoS One, 14(2), e0206309. North America (SCID-beige)
464. Wang, W., et al. (2019). J Clin Invest, 129(3), 1015-1029. North America (SCID-beige)
465. Assimon, V.A., et al. (2019). ACS Chem Biol, 14(2), 236-244. North America (SCID-beige)
466. Nachliely, M., et al. (2019). J Steroid Biochem Mol Biol, 188, 8-16. Israel (SCID-beige)
467. Harris, F.R., et al. (2019). Mol Oncol, 13(2), 132-152. North America (SCID-beige)
468. Adler-Levy, Y., et al. (2019). Sensors (Basel), 19(9). Israel (SCID-beige)
469. Ramirez, A.B. et al. (2019). BMC Cancer, 19(1), 220. North America (SCID-beige)
470. Schweppe, R.E., et al. (2019). Mol Cancer Res, 17(5), 1036-1048. North America (SCID-beige)
471. Shamai ,Y., et al. (2019). Stem Cells, 37(2), 176-189. Israel (SCID-beige)
472. Vandergaast, R., et al. (2019). Cancer Gene Ther, 27(3-4), 179-188. North America (SCID-beige)
473. Kim, I.S., et al. (2019). Nat Cell Biol, 21(9), 1113-1126. North America (SCID-beige)
474. Cai, D., et al. (2019). Nat Commun, 10(1), 4621. North America (CB-17)
475. Ceresa, D., et al. (2019). Int J Mol Sci, 20(16). Italy (NOD.SCID)
476. Aasen, S.N., et al. (2019). Mol Cancer Ther, 8(11), 2171-2181. Norway (NOD.SCID)
477. Arroyo-Crespo, J.J., et al. (2019). Int J Cancer, 145(8), 2267-2281. Spain (NOD.SCID)
478. Gatta, L.B., et al. (2019). Cancers (Basel), 11(9), pii: E1219. Italy (NOD.SCID)
479. Ghosh, S.,et al., Front Oncol, 9, 17. Israel (NOD.SCID)
480. Kalli, M., et al. (2019). Front Oncol, 9,32. Cyprus (NOD.SCID)
481. Ron, A., et al. (2019). Cancer Res, 79(18), 4767-4775. Germany (NOD.SCID)
482. Santoro, A., et al. (2019). Cell Rep, 26(3), 624-638.e8. Italy (NOD.SCID)
483. Schrama, D., et al. (2019). Int J Cancer, 145(4), 1020-1032. Germany (NOD.SCID)
484. Stafman, L.L., et al. Sci Rep, 9(1), 13259. North America (NOD.SCID)
485. Terrasi, A., et al. (2019). EBioMedicine, 41, 214-224. Italy (NOD.SCID)
486. Woosley, A.N., et al.Oncogene, 38(20), 3794-3811 North America (NOD.SCID)
487. Wu, J. et al. (2019). Nature, 572(7769), 402-406. North America (NOD.SCID)
488. Aasen, S.N., et al. (2019). Int J Mol Sci, 20(17). Norway (NOD.SCID)
489. Amodio, N., et al., (2019). Cancers (Basel), 18, 11(2). pii: E236. Italy (NOD.SCID)
490. Badarni, M., et al. (2019). JCI Insight, 5. pii: 125341. Israel (NOD.SCID)
491. Benguigui M, et al. (2019). Sci Rep, 9(1), 12613. Israel (NOD.SCID)
492. Falah, M., et al. (2019). Int J Mol Sci, 20(19). Israel (NOD.SCID)
493. Feng, Y., etal. (2019). J Exp Clin Cancer Res, 38(1), 54. China (NOD.SCID)
494. Hammer, S., et al. (2020) Clin Cancer Res, 26(8),1985-1996. Germany (NOD.SCID)
495. Hoogi, S., et al. (2019). J Immunother Cancer, 7(1), 243. Israel (NOD.SCID)
496. Krishnamoorthy, G.P., et al. (2019). Cancer Discov, 9(2), 264-281. North America (NOD.SCID)
497. La Rocca, F., et al. (2017). Cell Oncol (Dordr), 40(5), 483-496. Italy (NOD.SCID)
498. Otto, M., et al. (2019). Clin Oral Investig, 23(10), 3767-3775. Germany (NOD.SCID)
499. Punzi, S., et al. (2019). Breast Cancer Res, 21(1), 123. Italy (NOD.SCID)
500. Sharma, S. et al., (2019). EBioMedicine, 44, 194-208. North America (NOD.SCID)
501. Fusciello, M., etal. (2019). Nat Commun, 10(1), 5747. Canada (athymic nude mice)
502. Neiveyans, M., et al. (2019). Mabs, 11(3), 593-605. France (athymic nude mice)
503. Ryu, J.S., et al. (2019). Cancers (Basel), 11(4), pii: E574. Korea (athymic nude mice)
504. Sayyad M.R., et al. (2019). Breast Cancer Res Treat, 178(1), 35-49. North America (athymic nude mice)
505. Schweppe, R.E., et al. (2019). Mol Cancer Res, 17(5), 1036-1048. North America (athymic nude mice)
506. Stafman, L.L., et al. (2019). Transl Oncol, 12(2), 200-208. North America (athymic nude mice)
507. Akla B., et al. (2020). Mol Cancer Ther, 19(1), 168-177. France (athymic nude mice)
508. Assimon, V.A., et al. (2019). ACS Chem Biol, 14(2), 236-244. North America (athymic nude mice)
509. Belli, V., et al. (2019). Exp Clin Cancer Res, 38(1), 236. Italy (athymic nude mice)
510. Capasso, A., et al. (2019). Mol Cancer Ther,18(11), 1916-1925. North America (athymic nude mice)
511. Casagrande N., et al. (2019). Haematologica, 104(3), 564-575. Italy (athymic nude mice)
512. Duo, L., et al. (2019). Nat Commun, 10(1), 5051. China (athymic nude mice)
513. Eskra, J.N., et al. (2019). Prostate, 79(2), 223-233.North America (athymic nude mice)
514. Fok, J.H.L., et al. (2019). Nat Commun, 10(1), 5065. UK (athymic nude mice)
515. Formisano, L., et al. (2019). Nat Commun, 10(1), 1373. North America (athymic nude mice)
516. Hain, B.A., et al. (2019). JCSM Rapid Commun, 2(1), pii: e00075. North America (athymic nude mice)
517. Hegde, G.V., et al. (2019). Elife, 8, pii: e46551. North America (athymic nude mice)
518. Kietzman, W.B., et al. (2019). Mol Cancer Ther, 18(12), 2220-2232. North America (athymic nude mice)
519. Liu, P., et al. (2019). Nat Commun, 10(1), 1486. France (athymic nude mice)
520. Maaland, A.F., et al. (2019). Eur J Nucl Med Mol Imaging, 46(11), 2311-2321. Norway (athymic nude mice)
521. Moon, H.H. et al. (2019). Endocrinology, 160(8), 1786-1796. North America (athymic nude mice)
522. Nguyen, T., et al. (2019). Cell Rep, 27(2), 491-501.e6. North America (athymic nude mice)
523. Rello-Varona, S., et al. (2019). Sci Rep, 9(1), 3816. Spain (athymic nude mice)
524. Williams, A.P., et al. (2019). Transl Oncol, 12(10), 1364-1374. North America (athymic nude mice)
525. Wu, J., et al. (2019). Nature, 572(7769), 402-406. North America (athymic nude mice)
526. Yang, H., et al. (2019). Clin Cancer Res, 25(18), 5702-5716. North America (athymic nude mice)
527. Yang, L., et al. (2019). Sci Transl Med, 11(476). North America (athymic nude mice)
528. Chang, Y.C., et al. (2017). Sci Rep, 7(1), 9746. North America (RAG2 KO(SD))
529. Fisher, C., et al. (2019). J Clin Med, 8(12), pii: E2214. North American (RAG2 KO(SD))
530. Chen, Z.H., et al. (2019). J Exp Clin Cancer Res, 14;38(1), 196. China (B-NDG)
531. Chen, Z., et al. (2019). EBioMedicine, 47, 208-220. China (B-NDG)
532. Dai, K, et al. (2018). Eur J Immunol, 48(4), 683-695. China (B-NDG)
533. Li, Y., et al. (2018). J Exp Clin Cancer Res, 37(1), 276. China (B-NDG)
534. Sun, B., et al. (2019). Cancer Immunol Res, 7(11), 1813-1823. China (B-NDG)
535. Wang, J., et al. (2020). Thorac Cancer. China (B-NDG)
536. Wang, Q., et al. (2018). Clin Cancer Res, 24(4), 950-962. China (B-NDG)
537. Xia, J., et al. (2020). Mol Oncol, 14(4), 763-778. China (B-NDG)
538. Xiao, X., et al. (2017). Cell Death Dis, 8(9), e3050. China (B-NDG)
539. Ao, X., et al. (2019). J Immunother, 42(8), 284-296. China (B-NDG)
540. Chen, H.D., et al. (2020). Int J Biol Sci, 16(7), 1207-1217. China (B-NDG)
541. Gao , X., et al. (2019). Clin Cancer Res, 25(4), 1291-1301. China (B-NDG)
542. Gong, J., et al. (2020). Artif Cells Nanomed Biotechnol, 48(1), 408-414. China (B-NDG)
543. Chen, R., et al. (2020). Cancer Lett. 469, 162-172. China (B-NDG)
544. Huang W., et al. (2020). Cell Death Differ, 27(5), 1709-1727. China (B-NDG)
545. Lei, H., et al. (2019). Cancer Invest, 37(6), 242-252. China (B-NDG)
546. Sun, Y., et al. (2019). EBioMedicine, 43, 171-179. China (B-NDG)
547. Wang, D., et al. (2018). J Cell Mol Med, 22(12), 6202-6212. China (B-NDG)
548. Wu, R., et al. (2019). Pharmacol Res, 150, 104454. China (B-NDG)
549. Xiao, H., et al. (2019). Cancer Cell Int, 19, 218. China (B-NDG)
550. Yang, D. , et al. (2019). J Immunother Cancer, 7(1), 171. China (B-NDG)
551. Zhan, Y., et al. (2020). Mol Cancer, 19(1), 25. China (B-NDG)
552. Zhang, P., et al. (2020). J Biomed Sci, 27(1), 30. China (B-NDG)
553. Zhao, B., et al. (2019). Theranostics, 9(7), 1837-1850. China (B-NDG)
554. Wei, .T et al. (2020).mBio, 11(3):e00908-20. North America (athymic nude mice)
555. Tuominen, S., et al. (2020). Eur. J. Nucl. Med. Mol. Imaging, doi: 10.1007/s00259-020-05115-z. Finland (athymic nude mice)
556. Elwaie, TA., et al. (2020). J Med Chem. 2020 Dec 24;63(24):15906-15945. doi: 10.1021/acs.jmedchem.0c01647. North America (athymic nude mice)
557. Gómez-Aleza, C., et al. (2020). Nat Commun. 11(1):6335. Spain (athymic nude mice)
558. Parsels, LA., et al. (2020). Mol Cancer Ther. doi: 10.1158/1535-7163.MCT-20-0365. North America (athymic nude mice)
559. Gergen, AK., et al. (2020). J Surg Res, S0022-4804(20)30754-X. North America (athymic nude mice)
560. Gadkari, K., et al. (2020). Nutrients, 12(12):3631. North America (athymic nude mice)
561. Wu, Q., et al. (2020). Cell Death Dis, 11(11):1015. China (athymic nude mice)
562. Yi, J., et al. (2020). Proc Natl Acad Sci U S A, 117(49):31189-31197. North America (athymic nude mice)
563. Capone, E., (2020). Cancers (Basel), 12(10):2989. Italy (athymic nude mice)
564. Kim, SI., et al. (2020). Int J Mol Sci, 21(19):7326. North America (athymic nude mice)
565. Bownes, LV., et al. (2021). Transl Oncol,14(1):100893. North America (athymic nude mice)
566. Ridwan, SM., et al. (2020). Nanomedicine (Lond), 15(24):2369-2383. North America (athymic nude mice)
567. Scribner, JA., et al. (2020). Mol Cancer Ther, doi: 10.1158/1535-7163. North America (athymic nude mice)
568. Santich, BH., et al. (2021). Clin Cancer Res, 27(2):532-541. North America (athymic nude mice)
569. Roger, E., et al. (2020) Cells, 9(9):2110. Germany (athymic nude mice)
570. Sun, Y., et al. (2020). Cancer Res, 80(21):4840-4853. North America (athymic nude mice)
571. Dabaghi, M., et al. (2020). Cancers (Basel), 12(9):2562. Germany (athymic nude mice)
572. Ramachandran, S., and Srivasta, S. (2020). Mol Ther Oncolytics, 19:19-32. North America (athymic nude mice)
573. Shibata, M., et al. (2020). Mol Cancer Ther, 19(10):2175-2185. North America (athymic nude mice)
574. Guffanti, F., et al. (2020). Cancers (Basel), 12(9):2398. Italy (athymic nude mice)
575. Gomes, AP., et al. (2020). Nature, 585(7824):283-287. North America (athymic nude mice)
576. Gonzalez-Sanchez, L., et al. (2020). Carcinogenesis, 41(8):1113-1122. Spain (athymic nude mice)
577. Franklin, DA., et al. (2020). JCI Insight, 5(15):e134290. North America (athymic nude mice)
578. England, RM., et. al. (2020). Biomacromolecules, 21(8):3332-3341. UK (athymic nude mice)
579. Gelsomino, L., et al. (2020). Cancers (Basel), 12(8):2078. Italy (athymic nude mice)
580. Nwagwu, CD., et al. (2020). Lab Anim (NY), 49(8):227-232. North America (athymic nude mice)
581. Yan, P., et al, (2020). Cell Rep, 31(13):107840. North America (athymic nude mice)
582. Mohammadabadi, A., et al. (2020). Phys Med Biol, 65(12):125017. North America (athymic nude mice)
583. Chen. Y., et al. (2020). Prostate, 80(12):993-1005. North America (athymic nude mice)
584. Trotta, F., et al. (2020). Mol Cancer Ther, 19(9):1909-1921. Italy (athymic nude mice)
585. Siddique, AB., et al. (2020). Nutrients, 12(6):1749. North America (athymic nude mice)
586. Li, M., et al. (2020). Cancers (Basel),12(6):1538. North America (athymic nude mice)
587. Rossi, SM., et al. (2020). Br J Cancer, 123(3):369-377. Ireland (athymic nude mice)
588. Kennedy, AL., et al. (2020). Cancers (Basel), 12(5):1269. North America (athymic nude mice)
589. Sharick, JT., et al. (2020). Front Oncol, 10:553. North America (athymic nude mice)
590. Schregel, K., et al. (2020). Cancer Imaging, 20(1):35. North America (athymic nude mice)
591. Pattarawat, P., et al. (2020). Br J Cancer, 123(2):226-239. North America (athymic nude mice)
592. Gupta, K., et al. (2020). Front Oncol, 10:535. North America (athymic nude mice)
593. Humeau, J., et al. (2020). EMBO Mol Med. 12(5):e11622. North America (athymic nude mice)
594. Faugeroux, V., et al. (2020). Nat Commun,11(1):1884. North America (athymic nude mice)
595. Fell, JB., et al. (2020). J Med Chem, 63(13):6679-6693. North America (athymic nude mice)
596. Lingasamy, P., et al. (2020). Sci Rep, 10(1):5809. Estonia (athymic nude mice)
597. Tozzi, M., et al. (2020). Cancers (Basel), 12(3):640. Denmark (athymic nude mice)
598. Cam, M., et al. (2020). Neuro Oncol, 22(3):345-356. North America (athymic nude mice)
599. Wang, Y., et al. (2020). J Immunother Cancer. 8(1):e000462. doi: 10.1136/jitc-2019-000462. France (athymic nude mice)
600. Marayati, R., et al. (2020). J Pediatr Surg. 55(6):1072-1080. North America (athymic nude mice)
601. Peddi, S., et al. (2020). Biomacromolecules. 21(3):1091-1102. North America (athymic nude mice)
602. Bousquet Mur, E., et al. (2020). J Clin Invest, 130(2):612-624. France (athymic nude mice)
603. Dwivedi, SKD., et al. (2020). FASEB J. 34(2):2287-2300. North America (athymic nude mice)
604. Bhagwat, SV., et al. (2020). Mol Cancer Ther, 19(2):325-336. North America (athymic nude mice)
605. Sinha, S., et al. (2020). Oncogene, 39(6):1231-1245. North America (athymic nude mice)
606. Somwar, R., et al. (2020). Commun Biol. 23(1):776. North America (athymic nude mice)
607. Domínguez, JM., et al. (2020). J Hematol Oncol. 13(1):32. Spain (athymic nude mice)
608. Zheng, ZY., et al. (2020). Cancer Cell, 37(3):387-402.e7. North America (athymic nude mice)
609. Hammer, S., et al. (2020). Clin Cancer Res, 26(8):1985-1996. Germany (athymic nude mice)
610. Kenny, HA., et al. (2020). Mol Cancer Ther, 19(1):52-62. North America (athymic nude mice)
611. Shen, JZ., Cell, 184(2):352-369.e23. North America (athymic nude mice)
612. Rosenblum, D., et al. (2020). Sci Adv, 6(47):eabc9450. Israel (athymic nude mice)
613. Valle, S., et al. (2020). Nat Commun, 11(1):5265. Spain (athymic nude mice)
614. Alcalá, S., et al. (2020). Int J Mol Sci, 21(20):7437. Spain (athymic nude mice)
615. Zhang, H., et al. (2020). Mol Imaging Biol, 22(5):1184-1196. North America (athymic nude mice)
616. Tiwari, A., et al. (2020). Cancers (Basel), 12(10):2795. Germany (athymic nude mice)
617. Dadwal, UC., et al.. (2020). Int J Mol Sci, 21(18):6913. North America (athymic nude mice)
618. Mansi, R., et al. (2020). Molecules, 25(18):4155. Switzerland (athymic nude mice)
619. Chomet, M., et al. (2020). Eur J Nucl Med Mol Imaging. doi: 10.1007/s00259-020-05002-7.
620. Marcazzan, S., et al. (2020). Oral Dis. doi: 10.1111/odi.13592. North America (athymic nude mice)
621. Mansi, R., et al. (2020). EJNMMI Res, 10(1):90. Switzerland (athymic nude mice)
622. Miner, MW., et al. (2020). Mol Imaging Biol, 22(4):969-978. Finland (athymic nude mice)
623. VanOpstall, C., et al. (2020). Elife, 9:e53600. North America (athymic nude mice)
624. Verma, B, Wesa A. Curr Protoc Pharmacol. 89(1):e77. doi: 10.1002/cpph.77. North America (athymic nude mice)
625. Li, M., et al. (2020). Am J Transl Res, 12(5):1862-1872. North America (athymic nude mice)
626. Wei, SJ., et al. (2020). Cell Death Dis, 11(5):368. North America (athymic nude mice)
627. Li, J., et al. (2020). Light Sci Appl. 9:57. doi: 10.1038/s41377-020-0295-y. Germany (athymic nude mice)
628. Fanfone, D., et al. (2020). Biology (Basel), 9(3):53. Belgium (athymic nude mice)
629. Medeiros, B., et al. (2020). Cancers (Basel), 12(1):172. North America (athymic nude mice)
630. Maloney, R., et al. (2020). Methods Enzymol, 638:295-320. North America (athymic nude mice)
631. Shivange, G.,et al. (2020). J Vis Exp, (159). doi: 10.3791/60727. North America (athymic nude mice)
632. Shariati, M., et al. (2020). ACS Appl Mater Interfaces. 12(26):29024-29036. Belgium (athymic nude rats)
633. Chaves, C., et al. (2020). Pharmaceutics. 12(5):399. France (athymic nude mice)
634. Falvo, P., et al. (2020), Cancer Res, Feb 1;81(3):685-697. Italy (BALB/C)
635. Bonavita, E., et al. (2020). Immunity, 53(6):1215-1229.e8. UK (BALB/C)
636. Raineri, D., et al. (2020), Commun Biol, 3(1):615. Italy (BALB/C)
637. Suurs, FV., et al. (2020). EJNMMI Res. 10(1):111. Netherlands (BALB/C)
638. Di Tano, M., et al. (2020), Nat Commun. 11(1):2332. Italy (BALB/C)
639. Teijeira, Á., et al. (2020). Immunity, 52(5):856-871.e8. Spain (BALB/C)
640. Karp, NA., et al. (2020), Sci Rep, 10(1):6178. UK (BALB/C)
641. Kranjc Brezar, S., et al. (2020). Vaccines (Basel), 8(1):135. Slovenia (BALB/C)
642. Li, R., et al. (2020). Mol Cancer Ther 2019;18(12 Suppl):Abstract nr A016. North America (B-NDG)
643. Vigant, F., et al. (2020). Journal for ImmunoTherapy of Cancer; 8:doi: 10.1136/jitc-2020-SITC2020.0117. North America (B-NDG)
644. Pan, LN., et al. (2020). Cell Biol Int, doi: 10.1002/cbin.11524. China (B-NDG)
645. Hu, Z., et al. (2020). Mol Ther Oncolytics, 17:361-370. doi: 10.1016/j.omto.2020.04.008. China (B-NDG)
646. Liu, J., et al. (2020). JCI Insight, 5(12):e134728. doi: 10.1172/jci.insight. North America (B-NDG)
647. Cheng, H., et al. (2020). J Immunol, ;205(6):1497-1502. doi: 10.4049/jimmunol.2000136. China (B-NDG)
648. Lv, C., et al. (2020). Cell Mol Immunol, doi: 10.1038/s41423-020-0429-4. China (B-NDG)
649. Tu, C., et al. (2020). Theranostics, 11(5):2364-2380. doi: 10.7150/thno.47996. China (B-NDG)
650. Guan, L., etl al. (2020), Nan Fang Yi Ke Da Xue Xue Bao. 40(8):1200-1206. China (B-NDG)
651. Hu, XT., et al. (2020). J Exp Clin Cancer Res, 39(1):270. China (B-NDG)
652. Miao, JX., et al. (2020). World J Gastroenterol, 26(32):4802-4816. China (B-NDG)
653. Somwar, R., et al. (2020). Commun Biol, 3(1):776. North America (C.B-17 SCID)
654. Moquist, PN., et al. (2020). Mol Cancer Ther, 20(2):320-328. North America (C.B-17 SCID)
655. Thomas, A., et al. (2020). Cancers (Basel), 12(8):2279. North America (C.B-17 SCID)
656. Jones, RJ., et al. (2020). Front Immunol. 11:1816. North America (C.B-17 SCID)
657. Zhou, W., et al. (2020). Nat Commun, 11(1):3811. North America (C.B-17 SCID)
658. Jin, UH., et al. (2020). Cancers (Basel), 12(8):2097. North America (C.B-17 SCID)
659. McKnight, BN., et al. (2020). Breast Cancer Res, 22(1):37. North America (C.B-17 SCID)
660. Perrone, E., et al. (2020). Front Oncol, 10:118. North America (C.B-17 SCID)
661. Lopez, S., et al. (2020). Oncotarget, 11(5):560-570. North America (C.B-17 SCID)
662. Ghilu, S., et al. (2020). Cancer Chemother Pharmacol, 85(2):251-263. North America (C.B-17 SCID)
663. Han, C., et al. (2020). Gynecol Oncol, 156(2):430-438. North America (C.B-17 SCID)
664. Kang, L., et al. (2020). J Nucl Med, jnumed.120.246595. North America (C.B-17 SCID)
665. Maloney, R., et al. (2020). Methods Enzymol, 638:295-320. North America (C.B-17 SCID)
666. Bilger, A., et al. (2020). Viruses. 12(4):450. North America (athymic nude mice)
667. Liapis, E., et al. (2020). Cancer Res, 80(23):5291-5304. Germany (NOD SCID)
668. Zong, X., et al. (2020). Cancer Res, 80(20):4371-4385. North America (NOD SCID)
669. Solimando, AG., et al. (2020). Haematologica, Apr 30. doi: 10.3324/haematol.2019.239913. North America (NOD SCID)
670. Ronca, R., et al. (2020). Cancer Res, 80(11):2340-2354. Italy (NOD SCID)
671. Hammer, S., et al. (2020). Clin Cancer Res, 26(8):1985-1996. Norway (NOD SCID)
672. Gudlevičienė, Ž., et al. (2020). Medicina (Kaunas), 56(10):547. Lithuania (NOD SCID)
673. Kan, T., et al. (2020). J Immunother Cancer, 8(2):e001010. Israel (NOD SCID)
674. Barilani, M., et al. (2020). EBioMedicine, 57:102848. Italy (NOD SCID)
675. Valta, M., Transl Androl Urol, 9(3):1120-1134. Finland (NOD SCID)
676. Wei, W., et al. (2020). Adv Sci (Weinh), 7(13):1903595. China (R2G2®)
677. Maaland, AF., et al. (2020). PLoS One, 15(3):e0230526. Norway (R2G2®)
678. Chang, G., et al. (2020). Cancer Cell, 38(6):857-871.e7. North America (SCID/Beige)
679. Bartnicka, JJ., et al. (2020). Metallomics, 12(10):1508-1520. UK (SCID/Beige)
680. Gabay, M., et al. (2020). Cell Mol Neurobiol, doi: 10.1007/s10571-020-00969-1. Israel (SCID/Beige)
681. Colon-Otero, G.,et al. (2020). ESMO Open, 5(5):e000926. doi: 10.1136/esmoopen-2020-000926. North America (SCID/Beige)
682. Parhi, L., et al. (2020). Nat Commun, 11(1):3259. doi: 10.1038/s41467-020-16967-2. Israel (SCID/Beige)
683. Reddy, TP., et al. (2020). Breast Cancer Res, 22(1):48. North America (SCID/Beige)
684. De Thaye, E., et al. (2020). Sci Rep, 10(1):6688.  Belgium (SCID/Beige)
685. Zheng, ZY., et al. (2020). Cancer Cell, 37(3):387-402.e7. North America (SCID/Beige)
686. Ronca, R., et al. (2020). Cancer Res, 80(11):2340-2354. Italy (SCID/Beige)
687. Serebrenik, AA., et al. (2020). Clin Cancer Res, 26(13):3397-3407. North America (SCID/Beige)
688. Landolina, N., et al. (2020). Pharmacol Res, 158:104682. doi: 10.1016/j.phrs.2020.104682. Israel (SCID/Beige)
689. Satpathy, S., et al. (2020). Nat Commun.11(1):532. doi: 10.1038/s41467-020-14381-2. North America (SCID/Beige)
690. Santiago-O'Farrill, JM., et al. (2020). Cancer, 126(4):894-907. North America (SCID/Beige)
691. Farrera-Sal, M., et al. (2020). Int J Mol Sci, 21(14):5158. Spain (SCID/Beige)
Many factors can influence your selection of an appropriate research model. These published studies are identified to assist you in your selection. Envigo does not guarantee model performance in research studies.
The cell line abbreviation “(PDX)” is utilized as a generic naming convention of a “Patient-derived Xenograft” in absence of a formal name by the researcher(s).

 

Learn more

Paul<br>Knepley, DVM, Attending Veterinarian

Meet Paul
Knepley, DVM

Attending Veterinarian

View Profile View Profile  
Mandy<br>Horn, Scientist

Meet Mandy
Horn

Scientist

View Profile View Profile